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Abstract 
The glycoproteins of selected microbial pathogens often include highly modified 
carbohydrates such as 2,4-diacetamidobacillosamine (diNAcBac). These glycoconjugates are 
involved in host cell interactions and may be associated with the virulence of medically-
significant Gram-negative bacteria. In light of genetic studies demonstrating the attenuated 
virulence of bacterial strains in which modified carbohydrate biosynthesis enzymes have been 
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 2 
knocked out, we are developing small molecule inhibitors of selected enzymes as tools to evaluate 
whether such compounds modulate virulence.  
 We performed fragment-based and high-throughput screens against an amino-sugar 
acetyltransferase enzyme, PglD, involved in biosynthesis of UDP-diNAcBac in C. jejuni. Herein 
we report optimization of the hits into potent small molecule inhibitors (IC50 <300 nM). 
Biophysical characterization shows that the best inhibitors are competitive with acetyl coenzyme 
A and an X-ray co-crystal structure reveals that binding is biased towards occupation of the 
adenine sub-pocket of the AcCoA binding site by an aromatic ring.   
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 3 
Introduction 
Most clinically relevant antibiotics are targeted at essential bacterial survival functions 
including replication, transcription, translation, and cell wall biosynthesis.1 This is an outcome of 
in vitro antibiotic screening and discovery, which has relied on observing cell death in culture in 
laboratory settings. The emergence of resistance against all major mechanisms of antibiotic action 
requires new paradigms for combating infectious disease. A potentially promising approach 
includes the development of agents that target bacterial virulence in vivo in human hosts. Such 
approaches may mitigate the effects of infectious disease, while potentially resulting in less 
selective pressure for resistance development.2 Virulence factors are implicated in many bacterial 
processes including host-cell adhesion, invasion, and colonization, as well as quorum sensing and 
biofilm formation.2-5 In order to develop antivirulence agents, it is critical to identify validated 
pathogen-specific processes that cause virulence in the targeted human hosts.  
Protein glycosylation is widespread in nature and regulates a variety of cellular functions 
including protein folding, cell-cell interactions, cell signaling, and the host immune response.6 
Glycans are attached to proteins via either serine/threonine (O-linked) or the amide nitrogen of 
asparagine (N-linked). It is now recognized that selected bacteria possess the biosynthetic 
machinery for O- and/or N-glycosylation and that this modification may play a role in 
pathogenicity.7-11 N-glycosylation was first discovered in C. jejuni in 1999 and the protein 
glycosylation (pgl) pathway has been characterized in detail for this organism (Figure 1).12,13 In 
C. jejuni, more than 60 proteins, including confirmed virulence factors, are modified with a 
conserved heptasaccharide.14 
In a significant divergence between prokaryotes and eukaryotes, bacteria and archaea have 
specialized enzymatic processes to modify the structures of selected carbohydrates for 
incorporation into glycoconjugates. Furthermore, the discovery of unique prokaryote-specific 
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 4 
sugars is continuing with the pace of bacterial genome sequencing and bioanalytical methods 
development.7 In contrast to the glycosyltransferase enzymes, which assemble complex glycans 
and share common folds and mechanisms across domains of life, the specialized sugar-modifying 
enzymes are attractive targets for developing targeted antivirulence agents because they tend not 
to have mammalian homologs and because the associated glycoconjugates are linked with 
bacterial pathogenicity.15 Of particular interest is di-N-acetylbacillosamine (diNAcBac),16 which 
is derived from N-acetylglucosamine (GlcNAc). DiNAcBac is found, for example, at the reducing 
end of O-linked glycans in selected strains of N. gonorrhoeae and A. baumannii, and N-linked 
glycans in C. jejuni, highlighting the importance of diNAcBac biosynthesis pathways in these 
Gram-negative pathogens.17 Intriguingly, while protein glycosylation pathways from these 
pathogens glycosylate diverse proteins with different glycans, the reducing-end sugar is 
diNAcBac.18-20 The N-linked protein glycosylation (pgl) pathway of C. jejuni and steps leading to 
diNAcBac biosynthesis are illustrated in Figure 1. The first two steps of UDP-diNAcBac 
biosynthesis utilize an NAD+-dependent dehydratase (PglF) followed by a pyridoxal phosphate-
dependent aminotransferase (PglE) to produce a UDP-4-amino-sugar, which is then acetylated by 
PglD using acetyl coenzyme A (AcCoA) as a co-substrate (Figure 1 inset).18 Subsequent glycan 
assembly onto an undecaprenyl-diphosphate carrier, is catalyzed by a series of glycosyl 
transferases. After assembly, the completed heptasaccharide is translocated across the inner 
membrane and the glycan is transferred to protein substrates in the bacterial periplasm by the 
oligosaccharyl transferase PglB. 
Studies have shown that disruption of genes responsible for diNAcBac biosynthesis (pglF, 
pglE, pglD) perturb production of the native heptasaccharide glycosyl donor in C. jejuni.21 In 
addition, ΔpglD and ΔpglE strains show greatly reduced colonization of the gastrointestinal tract 
of 1-day-old chicks, thereby establishing a link between protein N-glycosylation and C. jejuni 
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 5 
pathogenicity in host cells.22 Further insight into these effects came from transposon mutagenesis 
experiments, which identified pglF and pglE as essential genes for colonization. In mice, 
mutation of pglE impaired invasion of intestinal epithelial cells and colonization of the gut.23 The 
causative glycoconjugates underpinning these findings remain unknown, but several molecular 
associations between N-glycosylation and C. jejuni virulence have been defined. For example, 
VirB10, a structural component to the type IV secretion system (TFSS), needs to be glycosylated 
at Asn97, otherwise a 10-fold decrease in natural competency results.24 Recently, 16 N-linked 
glycoproteins were identified and found to be associated with C. jejuni outer membrane vesicles 
(OMVs) including the PEB3 adhesin.25 Pathogens deploy OMVs to deliver bacterial proteins into 
host cells, making this an important finding in the relationship between periplasmic glycoproteins 
and virulence.26 Protein O-glycosylation is also associated with virulence; for example, loss of 
glycosylation of PilE, a constituent of the type IV pilin in N. gonorrhoeae, leads to a significant 
decrease in epithelial cell adhesion.27  
Herein we report the development of inhibitors targeting the C. jejuni PglD, a UDP-amino-
sugar acetyltransferase, which catalyzes the third step in diNAcBac biosynthesis. PglD represents 
an attractive target for inhibitor development as it is well understood from a structural and 
mechanistic perspective.28,29 Additionally, PglD is a soluble, well-expressed enzyme, which 
makes it tractable for structure/activity-driven inhibitor discovery. Crystallographic analysis of 
PglD reveals a homotrimeric structure with three equivalent active sites formed at the interfaces 
between adjacent protomers.28,29 Like many other bacterial UDP-amino-sugar acetyltransferases, 
PglD is a member of the left-handed β-helix family comprising two domains (Figure 2a); a N-
terminal domain with a β−α−β−α−β−α Rossmann fold motif that binds the UDP-4-amino-sugar, 
and a C-terminal hexapeptide repeat motif that defines the left-handed β-helix that contributes to 
the AcCoA binding site. PglD has been co-crystallized in the presence of the AcCoA and UDP-4-
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 6 
amino-sugar substrates (Figure 2b).28 The structural features of PglD and related homologs 
differentiate these prokaryotic AcCoA-dependent acetyltransferases from their mammalian 
counterparts, including for example HAT1 of the GCN5-related N-acetyltransferase (GNAT) 
superfamily.30  
Currently, many questions remain as to why modified carbohydrates, such as diNAcBac, 
are incorporated into bacterial glycoconjugates. Therefore, chemical tools such as small molecule 
inhibitors that selectively block diNAcBac biosynthesis would be valuable agents for 
understanding the significance of glycan diversification in selected bacteria. In addition, such 
tools could help to validate the pgl pathway enzymes as potential antivirulence targets. 
Consequently, we have established a program to develop inhibitors of diNAcBac biosynthesis 
with a focus on the well-characterized C. jejuni pathway. This Gram-negative pathogen is a 
common cause of gastroenteritis in humans and may also result in the development of Guillain-
Barré syndrome, an auto-immune disease in which the peripheral nerves are attacked resulting in 
damage to the myelin insulation.31,32 In recent years, C. jejuni has shown increased resistance 
towards front-line antibiotics including the macrolides and fluoroquinolones, which inhibit 
protein synthesis and DNA unwinding, respectively.33 
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 7 
Figure 1: Schematic representation of the C. jejuni N-linked protein glycosylation pathway. 
Enzymes are shown in italics with the oligosaccharyl transferase PglB shown as determined in 
PDB 3RCE. Also shown is an N-linked glycosylation substrate PEB3 (PDB: 2HXW), which is a 
virulence factor in periplasm that is modified by N-linked glycosylation. Inset highlights the three 
sugar-modifying enzymes that convert UDP-GlcNAc to UDP-diNAcBac. 
 
Results 
Screening  
 Initial hits for the development of inhibitors for PglD were identified by employing 
fragment-based screening and high-throughput molecular library approaches.34 The fragment-
based screen was performed with a fragment set that included a selection of the Maybridge Ro3 
chemical library as described previously.35 The primary screen involved differential scanning 
fluorimetry (DSF) analysis against PglD to identify fragments that bind to and stabilize the 
natively-folded protein. Following this, hits were confirmed by NMR spectroscopy 
(WaterLOGSY and STD) and further validated using a UV-based biochemical assay, which 
measures CoASH release following acetyl transfer to the UDP-4-amino-sugar.36 Using this 
workflow, 10 compound hits with IC50 values in the 1-10 mM range and ligand efficiencies in the 
0.29 – 0.32 range were validated. For example, compound 1 (Figure 2), which was analyzed by 
X-ray in complex with PglD, binds to the central AcCoA binding groove occupying the 
pantetheine site proximal to active-site residues involved in amino-sugar activation and thioester 
attack (Figure 2c). Unfortunately, efforts to build upon this, and other validated fragments yielded 
only modest improvements in affinity. Coincident with these studies a high-throughput screen 
was performed in collaboration with the Broad Institute, using a Diversity-Orientated Synthesis 
(DOS) compound collection (83,000) and the NIH Molecular Libraries Probe Production Centers 
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 8 
Network (MLPCN) library (276,000) of small molecules.37 Compounds were screened at 10 µM 
using a PglD end-point assay monitoring the generation of CoASH from the acetyltransferase 
reaction. Despite the low hit rate (defined as >20% inhibition) of 0.02% and 0.12% respectively, 
the screen led to the discovery of thienopyrimidinone-6-carboxylate compound 2 as a promising 
hit for further development. For direct comparison with the validated fragment hits, 2 was 
deconstructed to the core structure 3, which demonstrated a validated IC50 value of 860 µM and 
LE of 0.31. In light of these results and the tractability of the core towards synthetic manipulation 
at four points of diversification (C2, C4, C5, and C6; Scheme 1) this compound class became the 
focus of our continuing medicinal chemistry efforts.  
 Preliminary structure activity studies to vary substitution at C2 generated analog 4 as the 
best inhibitor with an IC50 value of 1 µM (LE 0.33). However, although this compound 
represented a good improvement in potency, the candidate suffered from some disadvantages. 
Specifically, 4 features a planar structure with poor solubility properties and a metabolic liability 
due to the 1,3-unsubsituted indole and conjugated alkene systems. Furthermore, 4 and related 
analogs showed poor long-term stability in solution. A significant effort was also made to 
crystallize PglD with several of the thienopyrimidinone hits, however, this proved unsuccessful. 
Therefore, we performed a docking study on fragment 3 to generate a computational model as a 
guide for future synthetic efforts aimed at eliminating the compound liabilities while improving 
potency.38 The thienopyrimidone-6-carboxylate core was predicted to occupy a binding site 
overlapping with the panthetheine moiety of AcCoA, as had been previously observed in the co-
crystal structure of fragment 1 (PDB 5TYH), with similar placement of the carboxylate moiety 
and close agreement between the positions of the furan oxygen of 1 and exocyclic oxygen of 2 
(compare Figure 2c and d). Given these observations, we exploited the computational model as a 
guide for the design of the next generation of analogs, which recognized the opportunity to extend 
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 9 
the molecule both at the C2 position to interact with a hydrophobic region on the β-helix, and at 
the C4 position, by transitioning to the thienopyrimidine core, to further occupy the AcCoA 
binding groove (Scheme 1).  
 
 
Figure 2: Structure analysis of C. jejuni PglD. (a) Crystal structure of the PglD homotrimer (PDB 
3BSY) in cartoon representation; individual protomers are colored in green, blue and orange. (b) 
Expanded of view of the PglD active site protein surface with the AcCoA substrate shown in stick 
representation (magenta, PDB 3BSY) as well as the UDP-4-amino-sugar substrate (yellow, PDB 
3BSS). (c) Crystal structure of fragment 1 (magenta) bound to PglD with a semi-transparent 
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surface and selected side-chain residues shown in stick representation and annotated (PDB 
5TYH). (d) Docking output pose generated for compound 3 (Glide, Maestro).38 
 
 
Scheme 1: General structure and numbering system of the thienopyrimidine core.  
In order to reach cytoplasmic targets in Gram-negative pathogens, compounds may enter 
cells through passive diffusion or pass through the bacterial porins to reach the periplasm and 
then reach the cytoplasm via passive or active mechanisms.39,40 With these parameters in mind, 
our overall goal was to develop potent (IC50 <500 nM) inhibitors of C. jejuni PglD based on the 
thienopyrimidine-6-carboxylate core with good ligand efficiency (LE >0.30) together with 
balanced physicochemical properties including cLogP values between 2 – 4.41 
 
Chemistry 
 We developed modular synthetic routes to provide access to the target thienopyrimidine 
carboxylic acids with readily-modifiable substitution at the C2 and C4 positions (Schemes 2 and 
3).  
For modification at the C2-position (Scheme 2, Route I), the synthesis was initiated by 
condensation of commercially available thiophene, 5, with nitriles bearing the desired R2 
substituent, under strongly acidic conditions. In most cases, the thienopyrimidone products of 
general structure 6, proved highly insoluble, and therefore chromatography and NMR 
characterization was carried out after the subsequent step. In cases where nitriles with the 
appropriate R2 moiety were inaccessible, an alternative approach (Route II) was employed. This 
route is somewhat longer and includes a Michaelis-Arbuzov reaction with triethyl phosphite and 
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 11 
analog 6 (Core structure: R2 = -CH2Cl) to furnish phosphonate 8. Subsequent Horner-Wadsworth-
Emmons (HWE) olefination and hydrogenation generated thienopyrimidinones of general 
structure 9 with a variety of phenylethyl substituents at the C2-position.  
 Installation of a substituent at the C4-position of thienopyrimidines is typically 
accomplished by transforming the C4 oxygen of the thienopyrimidone into chloride or bromide, 
with POCl3 and PBr3 respectively, followed by a SNAr reaction, both performed at high 
temperatures. To avoid use of these harsh conditions and strong lachrymators, we instead 
employed a one-step, room temperature reaction modified from chemistry developed by 
researchers at Wyeth.42 Utilization of a sufficiently strong base, such as 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), in excess solubilized the thienopyrimidinones in 
acetonitrile and replacing the toxic and expensive BOP reagent for the readily available PyBOP, 
allowed for robust formation of the desired pyrimidines of general structure 10 in good yields 
(40-90%). These thienopyrimidines could be isolated by column chromatography in excellent 
purity (>95% homogeneity as determined by LC-MS). The final saponification of 
thioenopyrimidine esters represented by 7 and 10 was achieved in a THF/MeOH/H2O mixture 
containing NaOH; occasionally mild heating was required to achieve complete conversion. The 
final inhibitors with core scaffold 11 were isolated by trituration as easy to handle solids. 
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Scheme 2: Synthesis of inhibitors with thienopyrimidine-6-carboxylate core 11 
Conditions: (a) 1.2 equiv. R2CN, 4 M HCl in 1,4-dioxane, 90°C (50-90%); (b) 1.5 equiv. R4NH2, 
1.3 equiv. PyBOP, 3 equiv. DBU, MeCN, RT (40-90%); (c) 1.2 equiv. ClCH2CN, 4 M HCl in 1,4-
dioxane, 90°C (50-90%) (d) 20 equiv. P(OEt)3, 145°C (85%); (e) 1.5 equiv. NaH, 2 equiv. 
ArCHO, THF, RT (70-90%); (f) 10% Pd(OH)2/C, THF/MeOH 1:1, 60°C (quant.); (g) 1.5 equiv. 
R4NH2, 1.3 equiv. PyBOP, 3 equiv. DBU, MeCN, RT (40-90%) (h) 3 equiv. NaOH, 
THF/MeOH/H2O 2:1:1, RT (50-80%).  
 
A related thienopyrimidine isomer with general structure 16, was accessed as described in 
Scheme 3. In this case, the thiophene starting material 14 is not commercially available but could 
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be readily prepared by the esterification of dicarboxylic acid 12 followed by nitration and 
hydrogenation. Condensation with nitriles provided thienopyrimidinones of general structure 15, 
which differ from the scaffold 11 series in the relative location of the sulfur atom and the absence 
of a methyl group on the thiophene ring. Installation of substituents at C4 and saponification were 
performed as described previously, to provide inhibitors with core scaffold 16. 
 
 
 
Scheme 3: Synthesis of inhibitors with thienopyrimidine-6-carboxylate core 16 
Conditions: (a) 4 equiv. SOCl2, MeOH, 50°C (99%); (b) 2 equiv. HNO3, H2SO4, RT; (c) 10% 
Pd(OH)2/C, THF/MeOH 1:1, RT (93% over 2 steps); (d) 1.2 equiv. R2CN, 4 M HCl in 1,4-
dioxane, 90°C (60-80%); (e) 1.5 equiv. R4NH2, 1.3 equiv. PyBOP, 3 equiv. DBU, MeCN, RT (40-
90%); (f) 3 equiv. NaOH in THF/MeOH/H2O 2:1:1, RT (50-80%). 
 
Initial SAR analysis 
 All target thienopyrimidine carboxylic acids 11 and 16 (Figure 3) were assayed for 
inhibition of recombinantly-expressed and purified C. jejuni NCTC 11168 PglD 
acetyltransferase.18 The continuous assay monitors the release of CoASH using 5,5'-dithiobis-(2-
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nitrobenzoic acid,36 and was carried out at 300 µM AcCoA (Km of 295 µM), and 500 µM UDP-4-
amino-sugar (Km of 274 µM). IC50 values of selected compounds are summarized in Table 1. The 
AcCoA concentration was aligned with reported physiologic concentrations in typical Gram-
negative bacteria.43  
 Our initial strategy was to explore the C2- and C4-substituents individually and then 
combine the optimal structural components from each series to capture advantageous synergistic 
binding effects. We observed that short aliphatic chains and saturated carbocycles at C2 (with R4 
= Me) provided weak inhibitors with IC50 values in the 10 µM to 1 mM range (data not shown). 
Based on these studies we selected an unsubstituted phenylethyl moiety (Figure 3, substituent d) 
as a favorable C2-substituent in terms of potency gain versus added mass (e.g. 17, IC50 = 2.2 µM, 
LE 0.35, Table 1). However, when we explored C4-substituents (with R2 = H), these analogs 
proved to be poor inhibitors (IC50 > 500 µM, data not shown) and SAR trends could not be well 
defined from the data. Accordingly, we elected to directly prepare disubstituted analogs, with R2 
= phenylethyl (d), and iteratively build up the R4 substituent in terms of length, sterics and 
heteroatom substitution (e.g. inhibitors 18-35; shorter and smaller substituents omitted for 
brevity). In general, only modest gains in potency could be achieved, and all the gains were at the 
cost of poorer ligand efficiencies. Ultimately, we observed that a phenylethyl moiety was also 
well tolerated at the C4-position of the thienopyrimidine core (20, R2 = R4 = phenylethyl, IC50 = 
1.4 µM).  
 In order to gain a better understanding of the binding behaviour of the inhibitors, we 
examined the results of the phenyl scan on the R4 substituent, which positioned moieties with 
different characteristics (sterics, polarity and hydrogen-bonding capabilities) ortho, meta or para 
on the aryl ring (inhibitors 21-35). However, while we had predicted that these substitutions 
would either complement or clash with the protein surface resulting in a measurable difference in 
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IC50 values, we instead observed a “flat" SAR with inhibitors exhibiting IC50 values around 0.5 
µM (e.g. 21-35). Indeed, only substitution with an acetamido group (33-35) elicited clear 
variances, with the ortho substitution being the most disfavored (35, IC50 = 9.0 µM). A potential 
explanation for the flat SAR could be that if the aryl group occupies the AcCoA binding groove 
then one edge would face the protein surface and the other would be solvent exposed, thus 
precluding any interaction between the moieties on the R4-aryl ring and the protein surface. This 
hypothesis was tested by preparing analogs bearing two moieties on the aryl ring (inhibitors 36-
38), however, potency remained at 0.5 µM. 
 In light of these data, we developed two hypotheses. One potential hypothesis was that the 
compounds might have a different mode of action other than competitive inhibition with the 
AcCoA substrate. We explored this by applying several biochemical and biophysical approaches, 
which are presented in the next section (vide infra). The second possibility was that the inhibitor 
binding mode differed significantly from that predicted by the computational model; for example, 
either the ligands bind in a different location on the PglD protein surface or the enzyme itself 
undergoes a significant conformational change. We also noted that the C2,C4-disubstituted 
inhibitors were inherently quite symmetrical, with a pseudo C2 axis of rotation in the plane of the 
thienopyrimidine core (Figure 4a). This feature might explain the flat SAR observed for the 
phenyl scan of the R4-substituent since the effect of any moiety on the aryl group could 
potentially be masked if the ligand flipped 180° and positioned the R2-substituent in the AcCoA 
binding groove instead. To test this hypothesis, we synthesized inhibitors 49 and 50, which 
included the quasi-regioisomeric thienopyrimidine core 16 and, if the binding orientation remains 
true, should position the sulfur atom towards the protein surface. Indeed, these inhibitors had 
similar potency to their parent analogs (compare 49 IC50 = 3.9 µM vs. 17 IC50 = 2.2 µM, and 50 
IC50 = 1.4 µM vs. 41 IC50 = 1.1 µM), suggesting the thienopyrimidine carboxylic core can bind in 
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either of two orientations into the AcCoA binding groove. To further validate this hypothesis, we 
developed inhibitors that would be locked in a fixed conformation by introducing rigidifying 
elements in the alkyl linkers between the thienopyrimidine core and substituent aryl groups. 
Synthetically it was straightforward to add a methyl group on the second carbon of the R2-
substituent and a methoxy group on the second carbon of the R4-substituent; the prerequisite 
starting materials were commercially available as both stereoisomers and could be easily 
transformed into the corresponding nitrile or amine for the modular syntheses (Figure 4b). With 
the four rigidified analogs we would expect to see data consistent with a matched/mismatched 
phenomenon; either substituent should have an enantiomer that complements the protein surface 
better than the other and when combined these effects should result in one poor inhibitor, two 
moderate ones and a single preferred analog. Indeed, this was observed with compounds 51-54 
(Figure 4b), albeit in a modest IC50 range. These combined results strongly suggested that the 
inhibitors were capable of binding to the PglD active site with either the R2-, or R4-substituent in 
the AcCoA groove. 
 Overall, the SAR data (Figure 4) shows that while binding may be somewhat promiscuous, 
the R2-substituent was far more important for binding potency. This experimental observation was 
therefore inconsistent with our initial computational model, which had oriented this substituent 
over the β-helix (and quite solvent exposed) and placed the R4-substituent in the AcCoA groove. 
These findings prompted us to investigate the binding mode in more detail, to provide a 
foundation for the next synthetic and biochemical efforts. 
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Figure 3: Representative examples of thienopyrimidine-6-carboxylate inhibitors of C. jejuni 
PglD; Core 11: R2 = a – z; R4 = a – z; Core 16: R2 = d, h; R4 = a. 
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Compound # Scaffold R2 R4 IC50/(µM) LE ΔTm/(°C) cLogP 
17 11 d a 2.2 ± 0.4 0.35 7.4 4.44 
18 11 d b 1.6 0.32 3.6 1.48 
19 11 d c 4.5 0.26 nd 5.89 
20 11 d d 1.4 0.27 13.2 6.54 
21 11 d g 0.54 0.27 nd 6.46 
22 11 d h 0.45 0.28 nd 6.46 
23 11 d i 0.48 0.28 13.7 6.46 
24 11 d j 0.42 0.29 nd 6.68 
25 11 d k 0.39 0.29 nd 6.68 
26 11 d l 0.48 0.29 13.2 6.68 
27 11 d m 0.72 0.28 nd 6.99 
28 11 d n 0.42 0.29 nd 6.99 
29 11 d o 0.25 0.30 14.3 6.99 
30 11 d p 0.39 0.30 12.0 5.04 
31 11 d q 0.34 0.30 12.0 5.04 
32 11 d r 0.42 0.30 12.5 5.04 
33 11 s a 2.4 0.29 nd 3.46 
34 11 t a 3.5 0.28 nd 3.46 
35 11 u a 9.0 0.26 nd 3.46 
36 11 d x 1.0 0.27 nd 6.42 
37 11 d y 0.37 0.26 nd 6.55 
38 11 d z 0.59 0.26 11.5 6.50 
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39 11 e a 4.4 0.31 7.9 4.97 
40 11 f a 4.1 0.30 7.4 5.50 
41 11 h a 1.1 ± 0.2 0.33 8.4 4.36 
42 11 k a 2.3 0.33 8.9 4.58 
43 11 q a 0.46 ± 0.05 0.39 8.4 2.94 
44 11 s b 1.4 0.28 5.3 0.50 
45 11 s r 0.28 0.27 11.5 4.06 
46 11 v a 2.1 0.33 9.4 5.15 
47 11 w a 4.6 0.28 7.4 5.32 
48 11 z a 1.8 0.31 7.4 4.41 
49 16 d a 3.9 0.34 4.8 4.45 
50 16 h a 1.4 0.34 5.9 4.37 
51 11 2PP(S) 2MPE(R) 2.0 0.24 9.4 6.50 
52 11 2PP(S) 2MPE(S) 1.1 0.25 10.4 6.50 
53 11 2PP(R) 2MPE(R) 0.87 0.27 nd 6.50 
54 11 2PP(R) 2MPE(S) 0.42 0.27 9.9 6.50 
55 11 s 2MPE(S) 0.27 ±  0.09 0.26 12.5 5.12 
 
Table 1: Experimental data obtained for selected inhibitors (Figures 3 and 4): IC50 values 
determined with the continuous C. jejuni PglD inhibition assay, calculated ligand efficiency (LE), 
thermal stabilization of the PglD/ligand complex with the DSF assay, and cLogP values 
calculated with built-in functionality of the ChemDraw® commercial software package. 
Compounds 51-54 (Figure 4): 2MPE: 2-methoxy-2-phenylethyl and 2PP: 2-phenylpropyl. 
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Figure 4: (a) Illustration of the quasi C2 symmetry axis of the disubstituted inhibitors (b) SAR of 
inhibitors 51 – 54 with rigidified R2 and R4 substituents; magenta symbols represent 
stereochemical preference of R2 and R4 substituents with respect to the PglD protein surface and 
highlight the mismatched/matched pattern. 
 
Biophysical characterization and inhibitor optimization 
 With the knowledge gained from SAR studies up to this point, we generated a potent C. 
jejuni PglD inhibitor, 55 (Figure 5), with an IC50 of 270 nM; however, this was at the cost of 
decreased ligand efficiency (0.26) and a high cLogP (5.12). In order to further optimize the 
potency and physicochemical properties of these compounds, we needed to better characterize 
their binding characteristics. Towards this end, we employed several complementary approaches 
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including the PglD inhibition assay with varying substrate concentrations, DSF analysis, dynamic 
light scattering (DLS) and X-ray crystallography. 
 We had first initiated inhibitor development based on modeling studies, which suggested 
that the thienopyrimidine carboxylate core competed with the AcCoA substrate for binding to the 
PglD active site. To test this experimentally, we monitored inhibition in the presence of varying 
concentrations of the two substrates. We observed that significantly higher concentrations of the 
UDP-4-amino-sugar substrate had no measurable effect on the inhibition by a representative 
analog of 11 (compound 37, supporting information Table S2). In contrast, a 2-, and 5-fold 
increase in AcCoA substrate concentration resulted in measured IC50 values of 0.63 µM and 1.4 
µM, respectively. These values represent a 2- and 4-fold decrease in potency and strongly suggest 
that the thienopyrimidine carboxylate inhibitors compete with AcCoA for binding to the PglD 
active site. 
All of the data thus far has been based on the enzymatic inhibition assay and, despite the 
judicious use of detergent and BSA to prevent aggregation phenomena,44 may be prone to 
artefacts that obscure binding trends. We therefore employed DSF as a qualitative secondary 
assay to assess binding of inhibitors to the C. jejuni PglD. DSF employs a fluorescent dye, Sypro 
Orange, to report on the thermal denaturation of a protein or protein/ligand complex.45 Potent 
inhibitors bind to their target enzyme more strongly that weak ones, resulting in a more stable 
protein/ligand complex and higher measured melting temperature (Tm). Therefore, the thermal 
stabilization (ΔTm) of PglD can be used to provide an indirect measure of the relative binding 
affinity of the related family of compounds. We selected a subset of inhibitors with a range of 
IC50 values and structural characteristics to analyze by DSF and plotted the ΔTm vs IC50 values 
(Figure 6). The graph shows a positive correlation (R2 = 0.72) between inhibition potency and 
thermal stabilization over a range of IC50 values indicating that the compounds stabilize the native 
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PglD homotrimer and that the more potent compounds, based on IC50 values, indeed stabilize 
PglD more effectively.  
Next, we analyzed the enzyme quaternary structure in solution by dynamic light scattering 
(DLS) and found the calculated hydrodynamic radius of apo PglD to be ~34 Å, consistent with the 
crystal structures of trimeric PglD (supporting information Figure S1). In the presence of 10-fold 
excess of inhibitor 55, the measured radius was marginally larger, ~36 Å, yet still consistent with 
the known trimeric structure. We also noted that the polydispersity index (PDI) of the PglD/55 
complex (24 % PDI) was lower than apo PglD (31% PDI), providing strong support that the 
inhibitor does not destabilize quaternary structure and indeed binds to the homotrimeric enzyme. 
Throughout these efforts we also continued to pursue crystallization attempts to gain 
structural insight on representative thienopyrimidine analogs. X-ray analysis of the C. jejuni 
NCTC 11168 PglD enzyme has been successfully carried out in our group and others.28,29 
Typically, the reported precipitant solutions were either high ionic strength (1.9 M ammonium 
sulfate) or contained acidic buffer components that were frequently observed to bind in the 
enzyme active site (sulfate, phosphate, citrate).28,29 Despite numerous attempts, application of 
previously published protocols did not yield co-crystal structures with the current 
thienopyrimidine-6-carboxylate inhibitors and thus we screened for new conditions that would be 
more compatible with the binding of small organic molecules. Ultimately, a crystallization hit 
with PEG-3350 was successfully optimized to reliably produce high quality crystals. The crystals 
develop as hollow, hexagonal rods that fill in from one end as they mature; producing either 
“vase-like” or solid crystals (Figure S3). The diffraction quality did not appear to differ between a 
solid or hollow end of such crystals. The crystals were tolerant of DMSO in concentrations up to 
10%, but tended to be rather fragile and could break upon looping. Therefore, we employed an 
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“in-drop soaking” protocol, in which a solution of the inhibitor is directly added to the drop 
containing the crystals. 
Using these crystallization conditions, we were able to obtain high-quality diffraction data 
and successfully solve the co-crystal structure of the PglD/17 complex (Figure 7 and S4). From 
the structure, two significant observations were immediately evident. Firstly, as anticipated from 
the SAR studies, the thienopyrimidine core was flipped 180° compared to the computational 
model developed with the core fragment, with the R2-subsituent binding in the AcCoA groove 
(Figure 7, panel b). This position of the thienopyrimidine core directs the R4-subsituent away 
from the AcCoA groove and into solvent where it makes no significant interactions with the PglD 
protein surface (Figure S5, LigPlot46). This observation is consistent with our SAR findings that 
R4-subsituent makes small contributions to inhibitor potency at the expense of ligand efficiency 
(Table 1). Secondly, the most surprising observation was that the ligand was bound 3.9 Å further 
along the AcCoA groove, relocating the carboxylate distal to the acetyltransferase active site 
where the AcCoA thioester is normally accommodated. This observation was rather unexpected as 
we assumed that the Asn118, H134 and S136 residues would be preferred hydrogen-bonding 
partners for the inhibitor carboxylic acid moiety. Furthermore, this displacement precludes a T-
shaped π-stacking between the side chain of Phe152 and the thienopyrimidine core; instead the 
binding mode positions Phe152 at an offset angle over the inhibitor carboxylate (Figure S4). To 
compensate, inhibitor 17 makes several other key interactions with the PglD surface; the 
carboxylic acid moiety is positioned at a favorable distance and orientation to form hydrogen 
bonds with the Ser136 side chain and the backbone amide NH of Ile155. Similarly, the 
thienopyrimidine N1 atom is well placed to interact with Gly173. From the structure it appears 
that a definitive interaction may be the placement of the R2 phenyl ring within the AcCoA adenine 
binding sub-pocket, displacing solvent waters from a relatively hydrophobic protein cavity. The 
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ligand binding mode is also internally favorable (low torsion) as the bound conformation adopts 
an anti-periplanar angle of approximately 160° along the benzylidene bond between the 
thienopyridimine core and R2 phenyl ring (Figure 7c). 
Armed with this new structural information we set out to further optimize the inhibitor 
series. First we investigated the possibility of simultaneously placing the R2 phenyl ring in the 
adenine sub-pocket and the carboxylate in the active site hot spot by increasing the linker length 
between the inhibitor core and R2-substituent. This did not prove successful as analogs 39 and 40 
(with a 3- and 4-carbon linker respectively) demonstrated lower in vitro potency; presumably due 
to internal strain of unfavorable torsion angles of the alkyl linker. Secondly we noted that 
although the R2 phenyl group fits well in the adenine sub-pocket, it does not fully occupy the 
volume of the [6,5]-fused ring cavity and there was unoccupied space at the meta position relative 
to the linker (Figure 7c). We explored several moieties at this position (41 –OMe, 42 –F, 46 –Cl 
and 47 –CF3, Table 1), but only gained a minor improvement in potency with compound 41 (IC50 
= 1.1 µM). Finally upon closer inspection of the adenine sub-pocket we speculated that if the 
aromatic carbon at a position ortho to the linker is replaced by a nitrogen and protonated, it would 
be well-oriented to form a hydrogen bond with the backbone oxygen of Gly173, as it does with 
the exocyclic amine of the adenine of the AcCoA substrate (PDB ID 3BSY).28 While the resultant 
pyridine nitrogen is only weakly basic, it could potentially be protonated in the microenvironment 
of the enzyme and lead to an order of magnitude improvement in potency. For example, the 
pyridine derivative risedronic acid is a ~300-fold more potent inhibitor of the human farnesyl 
pyrophosphate synthase than the corresponding phenyl analog.47 Although not as significant, the 
4.8-fold fold enhancement we observed between inhibitor 43 (IC50 = 0.46 µM) and 17 (IC50 = 2.2 
µM) is very interesting considering the minor nature of the structural change. Although 43 is not 
the most potent inhibitor, it exhibits the best ligand efficiency, 0.39, and has a cLogP of 2.94, 
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within the -0.5 - 3 range that is thought to be ideal to reach cytoplasmic targets of Gram-negative 
bacteria; with these characteristics 43 represents our best candidate to date with balanced 
physicochemical properties. 
 
 
Figure 5: Structures of key inhibitors discussed in this section: 17, 43 and 55.  
 
 
 
Figure 6: Correlation between the in vitro potency against PglD and the Tm (calculated from the 
first derivative of the thermal melting curve) of the PglD/inhibitor complexes with core 11; 
thermal melt assays were performed with 10 µM PglD and 100 µM compound. Correlation 
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coefficient provided for all data indicated by red diamond. Inhibitors with R4 = b (ethylamine) 
(blue diamond, circled) appear as outliers and are omitted from the calculation of the correlation 
coefficient. 
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Figure 7: Co-crystal structure of the PglD/17 complex (PDB 5T2Y). (a) Inhibitor 17 shown in 
sticks presentation (magenta) and overlayed with AcCoA substrate in lines (cyan, PDB 3BSY) 
and sugar substrate in sticks (yellow, PDB 3BSS). (b) overlay with the computational docking 
pose of compound 2 in line representation (orange). (c) Side-view highlighting the AcCoA 
adenine sub-pocket and interaction between 17 and residues Gly173, Ile155 and Ser136. White 
dashed lines indicate distances between 17 and PglD side-chain residues; yellow dashed line 
shows distance between the carboxylate computational docking pose and crystal structure. (d) 
Composite omit map 2Fo –Fc contoured at 1.0 s generated with the built in functionality of the 
PHENIX software and image generated in PYMOL. 
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Discussion and Conclusions 
In the development of inhibitors of the C. jejuni UDP-4-amino-sugar acetyltransferase, 
PglD, we initially screened both fragment-based and HTS libraries. These studies led to the 
identification of a thienopyrimidine-6-carboxylate core as a promising hit. Over the course of the 
SAR studies we found substitution at the C2-position of the core to be most impactful and that the 
binding mode appeared to be poorly predicted in silico. By combining data from substrate 
competition assays, DSF, and DLS we confirmed that the inhibitors bind exclusively to the 
AcCoA binding groove of the active site without disrupting the homo-trimeric structure of PglD.  
Critically, crystallographic analysis reveals a 180° flip of the thienopyrimidine core to 
place the R2-substituent in the AcCoA groove, as was anticipated from the SAR data. However, in 
contrast to previously characterized small fragments, we observed a 3.9 Å displacement of the 
inhibitor further along the AcCoA groove away from the known thioester binding site. Notably, in 
this new binding mode, the inhibitor makes several hydrogen-bonding interactions that 
compensate for the ones that would have been formed with the key catalytic residues (Asn118 & 
His134), but also precludes a stabilizing T-shaped π-interaction between the thienopyrimidine 
core and Phe152. Ultimately, it appears that placement of the R2-phenyl into the adenine sub-
pocket of AcCoA binding site may be the main driving force of ligand binding and indeed further 
optimization of this interaction resulted in to our most promising lead. Specifically, inhibitor 43 
(IC50 = 0.46 µM) shows an excellent ligand efficiency of 0.39 and a favorable clogP of 2.94. To 
the best of our knowledge this is the first competitive inhibitor with an IC50 value < 1 µM for a 
bacterial amino-sugar-modifying enzyme. A selection of inhibitors from the series presented 
herein was also tested against the structurally homologous amino-sugar acetyltransferase from N. 
gonorrhoeae (PglC in that O-linked glycosylation pathway) and no significant inhibition was 
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observed even at 100 µM. This observation was not surprising considering the significant 
differences between the AcCoA binding sites of the two enzymes.48 
With respect to biological analysis, the in vivo analysis of inhibitors that target bacterial 
virulence factors requires more complex experimental approaches than the simple estimation of 
minimal inhibitory concentrations (MICs) used in assessing bacterial viability with antibiotics 
that are targeted at cell survival processes. We are therefore pursuing multiple strategies to 
investigate in vivo efficacy both directly in C. jejuni, by assessing the impact of the inhibitors on 
glycoprotein biosynthesis, and in cell culture models of mammalian gut endothelia assessing C. 
jejuni adhesion and invasion. Currently, despite robust in vitro activity, we do not observe a 
reduction in glycosylation of periplasmic and cell surface proteins upon treatment of C. jejuni 
with the current inhibitors. This observation may be the result of insufficient inhibition potency 
against the target and/or may result from limited cellular uptake or efflux. In this context, C. 
jejuni features both a formidable cell wall including inner and outer cell membranes flanking a 
peptidoglycan barrier together with a dense external glycocalyx, as well as an active CmeABC 
efflux pump system to guard against external chemical agents.49 With respect to potency, the X-
ray analysis of PglD with compound 17 provides an excellent foundation for further structure-
guided optimization of the thienopyrimidine core. Concerning cellular uptake and efflux, which 
are common impediments to antibiotic activity in Gram-negative pathogens, the presented 
thienopyrimidine core also offers considerable opportunities. In particular, we are exploring 
several strategies including bioisosteric replacement of the carboxylate moiety and development 
of pro-drug analogs in consideration of the fact that the negative charge of the carboxylic acid 
moiety might acting as an impediment for compound uptake into the cytoplasm, which is the site 
of PglD activity. Additionally, the C4-substituent of the thienopyrimidine series represents a 
valuable handle for modulating the cLogP of the inhibitor, since we have demonstrated that 
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substitution at this site can be varied without adversely perturbing PglD inhibition. As elegantly 
demonstrated in a recent study of another Gram-negative pathogen, researchers have shown that 
fine-tuning the physical properties of inhibitors, in this case to mimic the zwitterionic charge 
distribution of amino acids, allowed novel carbapenem analogs to pass through the OccD1 
membrane porin of P. aeruginosa.50 Thus the thienopyrimidine compounds in this report are 
amenable to further such optimizations and current efforts are focused on overcoming the C. 
jejuni defenses to validate PglD as a potential antivirulence target in the biological context of 
infection.  
Overall the studies presented herein support further development of small molecule 
inhibitors as tools for investigating of the role diNAcBac in bacterial glycosylation and how it 
relates to pathogenicity. Promising candidates targeting important virulence factors have already 
been documented, including agents inhibiting pilus assembly in uropathogenic E. coli51 and 
bacterial motility by inhibiting disulfide formation of periplasmic proteins.52 Progress has also 
been made towards modulators of quorum sensing.53 Closely related to the work in this paper, the 
Sulea and Logan research groups have reported an inhibitor that targets the pseudaminic acid 
biosynthetic pathway found in H. pylori and C. jejuni.54 The “sialic-acid like” nonulosonate sugar 
product is required for the glycosylation of structural flagellin proteins and exposure to inhibitors 
attenuated flagellin production at concentrations of ≥100 µM. The flagella are required for 
persistent infections of H. pylori and this work demonstrates the link between bacterial 
glycosylation and pathogenicity using chemical tools (as opposed to genetic modification). The 
most advanced antivirulence work has been accomplished with N-phenyl-4-(3-
phenylthioureido)benzenesulfonamide, 56 (LED209), a prodrug agent that covalently inhibits 
QseC, a receptor involved in signaling between many Gram-negative pathogens and the infected 
host.55 Treatment with 56 in a mouse infection model showed prophylactic efficacy against S. 
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typhimurium and provided protection against F. tularensis both pre- and post-infection. 
Furthermore, 56 was not toxic at therapeutic doses and did not affect pathogen growth in vitro. 
These promising in vivo results are compelling evidence that killing is not necessarily required for 
treatment of bacterial infection and alternate therapeutic intervention strategies are worth 
exploring.  
In conclusion, herein we disclose the hit-to-lead development of a new series of 
thienopyrimidine-6-carboxylate inhibitors of the C. jejuni PglD UDP-amino-sugar 
acetyltransferase enzyme, which, upon further optimization could represent valuable chemical 
tools for unraveling the intricate biological role(s) of highly modified sugars in bacteria and 
potentially may lead to new agents with targeted antivirulence activity. 
 
Experimental section 
 
General Procedures for Characterization of Compounds. 
All intermediate compounds were purified by normal phase flash column chromatography on 
silica gel using a CombiFlash instrument. The homogeneity of all final compounds was confirmed 
to ≥95% by analytical reverse-phase LC-MS using an Agilent Series 1100 HPLC instrument 
equipped with a YMC AQ12S03-1003WT C18 column and a Finnigan LCQ Deca electrospray 
ionization mass spectrometer, using a gradient of 5-95% in 20 min of acetonitrile in water with 
0.1% TFA. Each final compound was fully characterized by 1H and 13C NMR and HRMS. 
Chemical shifts (δ) are reported in ppm relative to the internal deuterated solvent (1H, 13C), unless 
indicated otherwise. The high-resolution MS spectra of final products were recorded using direct 
analysis in real time (DART) ionization on a Bruker Daltonics APEXIV 4.7 Tesla Fourier 
Transform Ion Cyclotron Resonance Mass Spectrometer (FT-ICR-MS). 
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General procedure for the formation of thienopyrimidinones – Parent structure 6 
A pressure vessel washed charged with aminothiophene (1 equivalent) and nitrile (1-1.2 
equivalents) and 4M HCl in dioxane was added via syringe. The pressure vessel was tightly 
sealed with a Teflon screw cap stopper and the reaction was stirred at 80°C until the reaction was 
complete, as judged by TLC. The reaction mixture was cooled to room temperature, transferred to 
an Erlenmeyer flask in an ice-bath with a minimum volume of methanol and diluted with water 
(10-fold of solvent volume). The pH was brought to ~8 with ammonium hydroxide solution (25%) 
resulting in precipitate formation. The mixture was held on ice for 15-60 min and then filtered 
over filter paper; washing with distilled water. The residue was dried under vacuum to afford the 
desired thienopyrimidine in sufficient purity for the subsequent step. Due to the poor solubility of 
these compounds, full characterization was performed after the next synthetic step and 
purification. 
 
Ethyl 2-((diethoxyphosphoryl)methyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-
carboxylate (8)  
A 100 mL RBF was charged with ethyl 2-(chloromethyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-
d]pyrimidine-6-carboxylate (900 mg, 3.13 mmol) (6) and triethylphosphite (10.4 g, 10.8 mL, 62.8 
mmol) was added via syringe and the reaction was heated at 145 °C for 2 h. The reaction mixture 
was cooled down, diluted with 100 mL diethyl ether and stirred for 1 h on ice. The suspension 
was filtered, washed with copious amounts of ether and petroleum ether. The obtained residue 
was dried on high vacuum to furnish the desired the product as a fine, free-flowing white powder, 
994 mg (82%). 1H NMR (500 MHz, DMSO) δ 12.62 (s, NH), 4.28 (q, J = 7.1 Hz, 2H), 4.10 – 
3.99 (m, 4H), 3.37 (d, J = 22.2 Hz, 2H), 2.79 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.21 (t, J = 7.0 Hz, 
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6H). 13C NMR (126 MHz, DMSO) δ 166.99 (d, J = 3.0 Hz), 162.98, 159.97, 154.77 (d, J = 8.6 
Hz), 144.46, 122.93, 122.17, 63.42 (d, J = 6.3 Hz), 62.28, 33.99 (d, J = 131.2 Hz), 17.30 (d, J = 
6.0 Hz), 15.95, 15.29. 31P NMR (121 MHz, DMSO) δ 21.87. MS (ESI): calcd. 389.09; found 
389.07 [M+H]+. 
 
General procedure for the Horner-Wadsworth-Emmons reactions: 
To an ice-cooled solution of phosphonate 8 (1 equivalent) and aldehyde (3 equivalents) in 
anhydrous THF was added sodium hydride (60% suspension in mineral oil, 3 equivalents) in 
small portions. The reaction was stirred at RT until complete consumption of starting material, as 
determined by TLC. The crude product was poured into ice-water (5 times the reaction solvent 
volume), filtered and washed with water. The filter-cake was washed with ice-cold ethanol, 
diethyl ether and pentanes. The residue was dried on high vacuum to furnish the desired product 
in sufficient purity for subsequent reactions. 
 
General procedure for the hydrogenation reactions: 
A round bottom flask was charged with the alkene product from the HWE reaction, suspended in 
MeOH/THF/NH4OH 10:2:1 and purged with nitrogen. Pearlman’s catalyst was added (20% 
Pd(OH)2/C, 0.5 equivalents, CAS 12135-22-7), and the reaction mixture was purged with H2 gas 
and equipped with an H2-filled balloon. The reaction was stirred at 60°C until complete 
consumption of starting material, as determined by TLC, replenishing the H2 balloon as needed. 
The reaction mixture was purged with nitrogen and filtered through a plug of Celite, rinsing with 
EtOAc. The filtrate was concentrated in vacuo and the obtained material was used without further 
purification. 
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General procedure for the formation of ester precursors (10) 
To a solution of or thienopyrimidinone (1 equivalent) and (benzotriazol-1-yloxy)-
tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 1.3 equivalents) in anhydrous 
acetonitrile was added 1,8-diazabicyclo[5.4.0]undec-7-ene (1.5 equivalents, 3 equivalents in case 
of amine-HCl salts) via syringe. The mixture was stirred at RT for 5 min, after which the 
nucleophile (1.5 equivalents) was added and the reaction stirred at RT until complete 
consumption of starting material, as determined by TLC. The solvent was removed in vacuo and 
the crude residue was purified by column chromatography on silica gel using a gradient of EtOAc 
in 1:1 Hex/CH2Cl2. Note: Substituent b was introduced as a mono-Boc-protected diamine; the Boc 
protecting group was expediently removed by treating the compound with 4 M HCl in 1,4-
dioxane followed by precipitation with cold diethyl ether and filtration. 
 
Ethyl 5-methyl-4-(methylamino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 10(d,a) 
Isolated 80 mg (77% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.19 (m, 4H), 
7.17 – 7.12 (m, 1H), 7.09 (m, NH), 4.28 (q, J = 7.1 Hz, 2H), 3.09 – 3.04 (m, 2H), 3.02 – 2.97 (m, 
5H), 2.86 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.26, 167.97, 
163.50, 159.84, 142.72, 141.08, 129.47, 129.39, 126.92, 120.08, 115.95, 62.16, 41.31, 34.42, 
29.27, 16.74, 15.34. MS (ESI): calcd. 356.14; found 356.27 [M+H]+. 
 
Ethyl 4-((2-aminoethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,b) 
Isolated 70 mg (92% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.00 (br. s., NH2), 
7.48 (m, NH), 7.29 – 7.24 (m, 4H), 7.19 – 7.14 (m, 1H), 4.30 (q, J = 7.1 Hz, 2H), 3.81 (q, J = 5.6 
Hz, 2H), 3.12 – 3.03 (m, 6H), 2.95 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H).13C NMR (75 MHz, DMSO) δ 
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165.02, 162.48, 159.04, 141.38, 140.89, 129.04, 128.98, 126.75, 121.53, 116.43, 62.15, 38.60, 
38.41, 33.27, 16.21, 14.79. MS (ESI): calcd. 385.170; found 385.20 [M+H]+. 
 
Ethyl 4-(benzylamino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 10(d,c) 
Isolated 80 mg (79% yield) as an off-white solid. 1H NMR (500 MHz, DMSO) δ 7.70 (m, NH2), 
7.40 (d, J = 7.7 Hz, 2H), 7.29 (t, J = 7.6 Hz, 2H), 7.23 – 7.15 (m, 3H), 7.09 (m, 3H), 4.75 (d, J = 
5.8 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.93 (m, 7H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 168.26, 168.09, 163.46, 159.24, 142.59, 141.04, 140.88, 129.38, 129.33, 128.52, 
127.77, 126.85, 120.39, 115.86, 62.19, 45.07, 41.25, 34.27, 16.88, 15.31. MS (ESI): calcd. 
432.17; found 432.33 [M+H]+. 
 
Ethyl 5-methyl-2-phenethyl-4-(phenethylamino)thieno[2,3-d]pyrimidine-6-carboxylate 10(d,d)  
Isolated 106 mg (91% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.32 – 7.16 
(m, 8H & NH), 7.16 – 7.07 (m, 2H), 4.26 (q, J = 7.0 Hz, 2H), 3.72 (dd, J = 14.0, 6.3 Hz, 2H), 
3.13 – 3.05 (m, 2H), 3.05 – 2.96 (m, 2H), 2.94 – 2.86 (m, 2H), 2.79 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, DMSO) δ 168.22, 168.19, 163.44, 159.23, 142.67, 140.85, 140.67, 
129.82, 129.55, 129.40, 129.37, 127.29, 126.93, 120.27, 115.77, 62.14, 43.49, 41.29, 35.77, 
34.47, 16.60, 15.30. MS (ESI): calcd. 446.19; found 446.40 [M+H]+. 
 
Ethyl 4-((4-methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,g)  
Isolated 172 mg (83% yield) as an off-white solid. 1H NMR (500 MHz, DMSO) δ 7.26 – 7.20 (m, 
4H), 7.18 – 7.09 (m, 3H & NH), 6.86 (d, J = 8.6 Hz, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.71 – 3.66 
(m, 5H), 3.12 – 3.07 (m, 2H), 3.03 – 2.99 (m, 2H), 2.86 – 2.80 (m, 5H), 1.28 (t, J = 7.1 Hz, 3H). 
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13C NMR (75 MHz, CDCl3) δ 168.07, 163.30, 158.99, 158.70, 142.08, 138.32, 130.92, 130.03, 
128.70, 128.55, 126.07, 121.47, 115.33, 114.46, 61.45, 55.53, 42.47, 41.16, 34.55, 34.46, 15.70, 
14.58. MS (ESI): calcd. 476.20; found 476.40 [M+H]+. 
 
Ethyl 4-((3-methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,h)  
Isolated 182 mg (87% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.19 
(m, 6H), 7.17 – 7.11 (m, 1H 7 NH), 6.82 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.73 (m, 2H), 3.69 (s, 
3H), 3.10 (m, 2H), 3.01 (m, 2H), 2.91 – 2.86 (m, 2H), 2.82 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 168.05, 163.28, 160.23, 158.96, 142.08, 140.67, 138.35, 130.10, 
128.70, 128.56, 126.08, 121.47, 121.36, 115.34, 114.92, 112.13, 61.45, 55.39, 42.27, 41.18, 
35.41, 34.56, 15.66, 14.58. MS (ESI): calcd. 476.20; found 476.47 [M+H]+. 
 
Ethyl 4-((2-methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,i)  
Isolated 198 mg (95% yield) as a beige solid. 1H NMR (500 MHz, DMSO) δ 7.25 – 7.11 (m, 7H), 
7.08 (m, NH), 6.95 (d, J = 7.6 Hz, 1H), 6.86 (td, J = 7.4, 1.0 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 
3.74 (s, 3H), 3.73 – 3.68 (m, 2H) , 3.09 (m, 2H), 3.00 (m, 2H), 2.92 (t, J = 7.3 Hz, 2H), 2.81 (s, 
3H), 1.30 – 1.26 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 168.04, 163.38, 159.12, 157.72, 142.17, 
138.59, 130.92, 128.72, 128.54, 128.39, 127.51, 126.04, 121.11, 115.32, 110.79, 61.40, 55.61, 
41.84, 41.19, 34.53, 29.65, 15.62, 14.59. MS (ESI): calcd. 476.20; found 476.27 [M+H]+. 
 
Ethyl 4-((4-fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,j).  
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Isolated 183 mg (90% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.32 – 7.23 (m, 
4H), 7.21 – 7.12 (m, 3H), 7.02 (m, 2H), 5.61 (t, J = 5.5 Hz, NH), 4.34 (q, J = 7.1 Hz, 2H), 3.85 
(dd, J = 12.5, 6.8 Hz, 2H), 3.22 – 3.14 (m, 4H), 2.94 (m, 2H), 2.71 (s, 3H), 1.38 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 168.02, 163.25, 161.95 (d, J = 245.0 Hz), 158.92, 142.03, 
138.10, 134.79 (d, J = 3.3 Hz), 130.55, 130.44, 128.67, 128.57, 126.09, 121.68, 115.82 (d, J = 
21.2 Hz), 115.30, 61.49, 42.44, 41.14, 34.63, 34.54, 15.71, 14.57. MS (ESI): calcd. 464.18; found 
464.47 [M+H]+. 
 
Ethyl 4-((3-fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,k)  
Isolated 168 mg (83% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.23 (m, 
5H), 7.18 (m, 1H), 7.05 – 6.89 (m, 3H), 5.63 (t, J = 5.4 Hz, NH), 4.34 (q, J = 7.1 Hz, 2H), 3.87 
(dd, J = 12.5, 6.8 Hz, 2H), 3.23 – 3.15 (m, 4H), 2.96 (m, 2H), 2.72 (s, 3H), 1.38 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 168.01, 163.27 (d, J = 246.3 Hz), 163.23, 158.88, 142.02, 
141.77 (d, J = 7.1 Hz), 138.14, 130.49 (d, J = 8.3 Hz), 128.68, 128.57, 126.09, 124.78, 124.75, 
121.68, 115.90 (d, J = 20.9 Hz), 115.31, 113.88 (d, J = 21.0 Hz), 61.48, 42.17, 41.16, 35.21, 
34.56, 15.69, 14.57. MS (ESI): calcd. 464.18; found 464.47 [M+H]+. 
 
Ethyl 4-((2-fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,l)  
Isolated 170 mg (84% yield) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ 7.32 – 7.02 (m, 
9H), 5.69 (t, J = 5.4 Hz, NH), 4.35 (q, J = 7.1 Hz, 2H), 3.89 (dd, J = 12.4, 6.6 Hz, 2H), 3.23 – 
3.12 (m, 4H), 3.04 (m, 2H), 2.76 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
168.00, 163.30, 161.51 (d, J = 244.8 Hz), 158.99, 142.10, 138.29, 131.46 (d, J = 4.9 Hz), 128.86, 
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128.75, 128.70, 128.55, 126.08 (d, J = 16.0 Hz), 126.06, 124.60 (d, J = 3.5 Hz), 121.55, 115.75 
(d, J = 22.0 Hz), 115.31, 61.46, 41.41, 41.16, 34.52, 29.03, 15.68, 14.58. MS (ESI): calcd. 
464.18; found 464.47 [M+H]+. 
 
Ethyl 5-methyl-4-((4-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,m)  
Isolated 103 mg (77% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.10 (m, 9H), 
5.61 (t, J = 5.3 Hz, NH), 4.35 (q, J = 7.1 Hz, 2H), 3.88 (dd, J = 12.2, 6.6 Hz, 2H), 3.24 – 3.13 (m, 
4H), 2.95 (t, J = 6.7 Hz, 2H), 2.69 (s, 3H), 2.36 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 168.09, 163.33, 159.00, 142.11, 138.36, 136.59, 135.89, 129.76, 128.96, 128.71, 
128.56, 126.07, 121.45, 115.34, 61.44, 42.41, 41.19, 34.93, 34.57, 21.32, 15.68, 14.59. MS (ESI): 
calcd. 460.21; found 460.47 [M+H]+. 
 
Ethyl 5-methyl-4-((3-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,n) 
Isolated 113 mg (84% yield) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.16 (m, 
6H), 7.07 (m, 3H), 5.61 (t, J = 5.3 Hz, NH), 4.35 (q, J = 7.1 Hz, 2H), 3.89 (dd, J = 12.2, 6.6 Hz, 
2H), 3.19 (m, 4H), 2.95 (t, J = 6.7 Hz, 2H), 2.69 (s, 3H), 2.36 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 168.09, 163.31, 159.00, 142.11, 138.97, 138.74, 138.33, 129.89, 
129.03, 128.71, 128.56, 127.79, 126.09, 126.07, 121.46, 115.36, 61.45, 42.36, 41.20, 35.29, 
34.58, 21.66, 15.61, 14.58. MS (ESI): calcd. 460.21; found 460.50 [M+H]+. 
 
Ethyl 5-methyl-4-((2-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,o)  
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Isolated 101 mg (75% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.33 – 7.14 (m, 
9H), 5.68 (t, J = 5.5 Hz, NH), 4.36 (q, J = 7.1 Hz, 2H), 3.87 (dd, J = 12.8, 7.0 Hz, 2H), 3.19 (m, 
4H), 3.01 (t, J = 7.1 Hz, 2H), 2.76 (s, 3H), 2.41 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 168.10, 163.32, 159.09, 142.07, 138.29, 137.10, 136.71, 130.94, 129.79, 128.70, 
128.57, 127.16, 126.48, 126.09, 121.56, 115.35, 61.47, 41.30, 41.13, 34.69, 32.99, 19.71, 15.79, 
14.59. MS (ESI): calcd. 460.21; found 460.47 [M+H]+. 
 
Ethyl 5-methyl-2-phenethyl-4-((2-(pyridin-4-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(d,p)  
Isolated 70 mg (72% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 8.45 (d, J = 5.9 
Hz, 2H), 7.25 (d, J = 6.0 Hz, 2H), 7.22 (m, 4H), 7.18 (br. t, J = 5.8 Hz, NH), 7.13 (m, 1H), 4.28 
(q, J = 7.1 Hz, 2H), 3.77 (dd, J = 13.5, 6.5 Hz, 2H), 3.10 – 3.05 (m, 2H), 3.03 – 2.98 (m, 2H), 
2.92 (dd, J = 10.3, 4.0 Hz, 2H), 2.81 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 168.27, 159.30, 150.69, 149.70, 140.91, 129.45, 127.00, 125.50, 62.28, 42.30, 35.00, 
34.48, 16.68, 15.37. MS (ESI): calcd. 447.185; found 447.20 [M+H]+. 
 
Ethyl 5-methyl-2-phenethyl-4-((2-(pyridin-3-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(d,q)  
Isolated 54 mg (41% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 8.46 (s, 1H), 
8.41 (d, J = 4.5 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.31 (dd, J = 7.7, 4.8 Hz, 1H), 7.25 – 7.21 (m, 
4H), 7.19 – 7.12 (m, NH, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.76 (dd, J = 13.1, 6.7 Hz, 2H), 3.10 – 
3.05 (m, 2H), 3.00 (dd, J = 8.4, 6.2 Hz, 2H), 2.93 (t, J = 7.1 Hz, 2H), 2.81 (s, 3H), 1.29 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.19, 163.47, 159.26, 151.00, 148.56, 142.66, 140.86, 
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137.49, 136.20, 129.41, 126.95, 124.63, 120.37, 115.78, 62.21, 42.92, 41.25, 34.48, 32.87, 16.65, 
15.32. MS (ESI): calcd. 447.185; found 447.27 [M+H]+. 
 
Ethyl 5-methyl-2-phenethyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(d,r)  
Isolated 118 mg (90% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.52 (dd, J = 
5.8, 1.7 Hz, 1H), 7.62 (td, J = 7.7, 1.8 Hz, 1H), 7.49 (s, NH), 7.31 – 7.23 (m, 4H), 7.21 – 7.13 (m, 
3H), 4.34 (q, J = 7.1 Hz, 2H), 4.02 (dd, J = 11.5, 5.2 Hz, 2H), 3.19 – 3.06 (m, 6H), 2.97 (s, 3H), 
1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.08, 168.01, 163.46, 160.33, 158.80, 
149.13, 142.21, 139.20, 137.12, 128.71, 128.51, 126.00, 123.76, 122.02, 120.96, 115.53, 61.35, 
41.19, 40.27, 36.09, 34.56, 15.79, 14.60. MS (ESI): calcd. 447.19; found 447.40 [M+H]+. 
 
Ethyl 4-((2,3-dihydro-1H-inden-2-yl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,x)  
Isolated 105 mg (79% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.33 – 7.17 (m, 
9H), 5.82 (d, J = 6.7 Hz, NH), 5.13 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.52 (d, J = 7.3 Hz, 2H), 
3.46 (d, J = 7.2 Hz, 2H), 2.95 (d, J = 5.4 Hz, 2H), 2.89 (d, J = 5.5 Hz, 2H), 2.84 (s, 3H), 1.40 (t, J 
= 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.03, 163.28, 158.79, 142.05, 141.03, 138.10, 
O128.71, 128.57, 127.14, 126.08, 125.10, 121.73, 115.31, 61.49, 52.48, 41.12, 40.45, 34.57, 
15.88, 14.58. MS (ESI): calcd. 458.19; found 458.47 [M+H]+. 
 
Ethyl 4-((3,5-dimethoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,y)  
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Isolated 77 mg (52% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.23 (m, 4H), 
7.16 – 7.09 (m, 1H, NH), 6.41 (s, 2H), 6.33 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.73 (dd, J = 13.7, 
6.3 Hz, 2H), 3.67 (s, 6H), 3.10 (m, 2H), 3.04 – 2.98 (m, 2H), 2.88 – 2.79 (m, 5H), 1.29 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.21, 168.18, 163.44, 161.61, 159.23, 142.96, 142.67, 
140.85, 129.39, 129.37, 126.94, 120.26, 115.78, 107.80, 99.12, 62.15, 56.10, 43.39, 41.34, 36.05, 
34.48, 16.60, 15.29. MS (ESI): calcd. 506.21; found 506.53 [M+H]+ 
 
Ethyl 4-((2-(benzo[d][1,3]dioxol-5-yl)ethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-
6-carboxylate 10(d,z)  
Isolated 94 mg (66% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.20 (m, 
4H), 7.10 (s, 1H, NH), 6.85 – 6.79 (m, 2H), 6.68 (d, J = 7.9 Hz, 1H), 5.95 (s, 2H), 4.28 (q, J = 7.1 
Hz, 2H), 3.69 (dd, J = 14.1, 6.3 Hz, 2H), 3.12 – 3.05 (m, 2H), 3.05 – 2.95 (m, 2H), 2.85 – 2.78 
(m, 5H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.19, 163.45, 159.23, 148.42, 
146.70, 142.67, 140.87, 134.41, 129.40, 129.38, 126.94, 122.67, 120.25, 115.76, 110.12, 109.30, 
101.84, 62.15, 43.63, 41.32, 35.45, 34.49, 16.62, 15.31. MS (ESI): calcd. 490.18; found 490.47 
[M+H]+. 
 
Ethyl 5-methyl-4-(methylamino)-2-(3-phenylpropyl)thieno[2,3-d]pyrimidine-6-carboxylate 
10(e,a)  
Isolated 52 mg (33% yield) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 – 7.14 (m, 5H), 
5.67 (m, NH), 4.33 (q, J = 7.1 Hz, 2H), 3.12 (d, J = 4.8 Hz, 3H), 2.88 (s, 3H), 2.84 (m, 2H), 2.75 
– 2.67 (m, 2H), 2.22 – 2.11 (m, 2H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
168.72, 167.83, 163.32, 159.61, 142.63, 138.32, 128.75, 128.45, 125.88, 121.25, 115.33, 61.42, 
39.21, 35.91, 30.26, 28.33, 15.93, 14.56. MS (ESI): calcd. 370.159; found 370.33 [M+H]+ 
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Ethyl 5-methyl-4-(methylamino)-2-(4-phenylbutyl)thieno[2,3-d]pyrimidine-6-carboxylate 10(f,a)  
Isolated 88 mg (43 % yield) as a pale yellow syrup. 1H NMR (300 MHz, CDCl3) δ 7.29 – 7.13 (m, 
5H), 5.64 (br. m, NH), 4.34 (q, J = 7.1 Hz, 2H), 3.11 (d, J = 4.8 Hz, 3H), 2.89 (s, 3H), 2.88 – 2.81 
(m, 2H), 2.70 – 2.63 (m, 2H), 1.95 – 1.83 (m, 2H), 1.78 – 1.67 (m, 2H), 1.38 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 168.96, 167.88, 163.35, 159.64, 142.89, 138.27, 128.65, 128.43, 
125.80, 121.27, 115.32, 61.42, 39.51, 36.06, 31.51, 28.30, 15.95, 14.57. MS (ESI): calcd. 
384.175; found 384.27 [M+H]+. 
 
Ethyl 2-(3-methoxyphenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(h,a)  
Isolated 163 mg (83% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.16 (t, J = 7.8 
Hz, 1H), 6.84 (m, 2H), 6.70 (dd, J = 8.1, 2.5 Hz, 1H), 5.66 (br. m, NH), 4.33 (q, J = 7.1 Hz, 2H), 
3.75 (s, 3H), 3.15 – 3.08 (m, 7H), 2.86 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 167.96, 163.29, 159.77, 159.61, 143.75, 138.29, 129.46, 121.37, 121.09, 115.41, 
114.25, 111.53, 61.44, 55.32, 41.06, 34.48, 28.32, 15.90, 14.56. MS (ESI): calcd. 386.154; found 
386.27 [M+H]+. 
 
Ethyl 2-(3-fluorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(k,a)  
Isolated 141 mg (54% yield) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.21 – 7.13 (m, 
1H), 7.05 – 6.92 (m, 2H), 6.84 (td, J = 8.5, 2.6 Hz, 1H), 5.66 (br. m, NH), 4.33 (q, J = 7.1 Hz, 
2H), 3.17 – 3.06 (m, 7H), 2.88 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
167.80, 167.58, 164.66, 163.28, 161.41, 159.61, 144.70 (d, J = 7.2 Hz), 138.21, 129.85 (d, J = 8.4 
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Hz), 124.34 (d, J = 2.6 Hz), 121.51, 115.42 (d, J = 3.6 Hz), 112.84 (d, J = 21.0 Hz), 61.46, 40.67, 
34.02, 28.32, 15.92, 14.54. MS (ESI): calcd. 374.134; found 374.20 [M+H]+. 
 
Ethyl 5-methyl-4-(methylamino)-2-(2-(pyridin-2-yl)ethyl)thieno[2,3-d]pyrimidine-6-carboxylate 
10(q,a)  
Isolated 585 mg (57% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.54 (ddd, J = 5.0, 
1.7, 0.8 Hz, 1H), 7.65 (td, J = 7.7, 1.8 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.17 (ddd, J = 7.5, 5.0, 
1.1 Hz, 1H), 5.68 (br. m, NH), 4.34 (q, J = 7.1 Hz, 2H), 3.45 – 3.35 (m, 2H), 3.29 (m, 2H), 3.08 
(d, J = 4.7 Hz, 3H), 2.91 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 167.41, 
163.29, 161.18, 159.61, 148.18, 138.21, 137.73, 123.64, 121.71, 121.59, 115.48, 61.47, 38.68, 
35.79, 28.39, 15.96, 14.55. MS (ESI): calcd. 357.139; found 357.20 [M+H]+. 
 
 
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(s,a)  
Isolated 38 mg (68% yield) as a beige solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NHAc), 7.41 
(d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 7.09 (m, NH), 4.27 (q, J = 7.1 Hz, 2H), 3.02 – 2.94 
(m, 7H), 2.86 (s, 3H), 1.98 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3 + 
CD3OD) δ 174.50, 172.26, 171.43, 167.85, 164.01, 143.40, 142.04, 140.74, 133.30, 125.53, 
124.67, 119.90, 65.95, 45.18, 38.26, 32.49, 28.11, 19.95, 18.70. MS (ESI): calcd. 413.16; found 
413.33 [M+H]+. 
 
Ethyl 2-(4-acetamidophenethyl)-4-((2-aminoethyl)amino)-5-methylthieno[2,3-d]pyrimidine-6-
carboxylate 10(s,b)  
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Isolated 51 mg (83 % yield) as a white solid. 1H NMR (300 MHz, DMSO) δ 9.81 (s, NHAc), 7.43 
(d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.07 – 6.96 (m, NH), 4.26 (q, J = 7.0 Hz, 2H), 3.57 
(dd, J = 11.0, 5.5 Hz, 2H), 3.23 (dd, J = 11.6, 6.1 Hz, 2H), 3.03 – 2.90 (m, 4H), 2.86 (s, 3H), 1.99 
(s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 167.69, 162.98, 159.06, 156.71, 
140.62, 137.83, 136.80, 129.09, 119.63, 115.35, 78.38, 61.67, 33.38, 24.59, 21.41, 16.11, 14.81. 
MS (ESI): calcd. 442.191; found 442.27 [M+H]+. 
 
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-((2-(pyridin-4-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(s,p)  
Isolated 86 mg (68% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NHAc), 
8.46 (d, J = 4.7 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.24 (m, 2H, NH), 7.12 (d, J = 8.2 Hz, 2H), 
4.26 (q, J = 7.0 Hz, 2H), 3.76 (dd, J = 12.7, 6.4 Hz, 2H), 3.07 – 2.90 (m, 6H), 2.79 (s, 3H), 2.00 
(s, 3H), 1.28 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 169.24, 168.18, 163.44, 159.18, 
150.63, 149.67, 140.79, 138.35, 137.19, 129.51, 129.43, 129.38, 125.41, 120.15, 115.75, 62.17, 
46.92, 41.32, 34.98, 33.91, 25.05, 16.61, 15.28. MS (ESI): calcd. 504.207; found 504.13 [M+H]+. 
 
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-((2-(pyridin-3-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(s,q)  
Isolated 79 mg (63% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NHAc), 
8.41 (d, J = 4.7 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.46 (m, J = 15.7, 8.4 Hz, 3H), 7.30 (dd, J = 
7.7, 4.8 Hz, 1H), 7.18 – 7.10 (m, 2H, NH), 4.27 (q, J = 7.0 Hz, 2H), 3.76 (dd, J = 12.9, 6.6 Hz, 
2H), 3.06 – 2.91 (m, 6H), 2.80 (s, 3H), 2.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 168.20, 163.45, 159.23, 151.01, 148.58, 140.83, 137.41, 137.19, 136.19, 129.62, 
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129.52, 124.60, 120.22, 120.13, 115.75, 62.18, 47.02, 33.93, 32.88, 27.10, 25.06, 16.63, 15.30. 
MS (ESI): calcd. 504.207; found 504.27 [M+H]+. 
 
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(s,r)  
Isolated 55 mg (44% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NHAc), 
8.52 (d, J = 4.1 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.43 (m, 2H, NH), 7.28 (d, J = 7.4 Hz, 1H), 
7.24 (dd, J = 7.4, 4.9 Hz, 1H), 7.14 (d, J = 8.3 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 3.88 (dd, J = 
12.3, 6.4 Hz, 2H), 3.09 (m, 2H), 3.05 – 2.99 (m, 2H), 2.96 (dd, J = 8.2, 6.3 Hz, 2H), 2.84 (s, 3H), 
2.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 169.20, 168.29, 168.13, 
163.46, 160.72, 159.20, 150.13, 140.80, 138.33, 137.87, 137.24, 129.56, 124.47, 122.79, 120.33, 
120.14, 115.79, 62.17, 41.60, 41.33, 37.36, 33.85, 25.09, 16.52, 15.31. MS (ESI): calcd. 504.207; 
found 504.20 [M+H]+. 
 
Ethyl 2-(3-acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(t,a)  
Isolated 45 mg (81% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.84 (s, NHAc), 
7.47 (s, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.14 (t, J = 7.8 Hz, 1H), 7.11 (m, J = 4.5 Hz, NH), 6.90 (d, 
J = 7.6 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.04 – 2.94 (m, 7H), 2.87 (s, 3H), 2.00 (s, 3H), 1.28 (t, 
J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3 + CD3OD) δ 174.50, 172.26, 171.43, 167.85, 
164.01, 143.40, 142.04, 140.74, 133.30, 125.53, 124.67, 119.90, 65.95, 45.18, 38.26, 32.49, 
28.11, 19.95, 18.70. MS (ESI): calcd. 413.16; found 413.30 [M+H]+. 
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Ethyl 2-(2-acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(u,a)  
Isolated 35 mg (63% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.43 (s, NHAc), 
7.29 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 7.08 (m, NH, 1H), 
4.27 (q, J = 7.1 Hz, 2H), 3.03 (m, 2H), 2.97 (d, J = 4.5 Hz, 3H), 2.93 (m, 2H), 2.86 (s, 3H), 2.03 
(s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3 + CD3OD) δ 175.11, 172.05, 
171.24, 167.71, 164.02, 143.67, 139.66, 139.37, 134.36, 131.18, 130.57, 130.32, 125.54, 120.05, 
66.02, 44.45, 33.67, 32.49, 28.01, 19.89, 18.71. MS (ESI): calcd. 413.16; found 413.10 [M+H]+. 
 
Ethyl 2-(3-chlorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(v,a)  
Isolated 122 mg (47% yield) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (m, 1H), 
7.15 – 7.08 (m, 3H), 5.65 (br. m, NH), 4.32 (q, J = 7.1 Hz, 2H), 3.13 – 3.08 (m, 7H), 2.87 (s, 3H), 
1.36 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 167.77, 167.51, 163.26, 159.59, 144.15, 
138.23, 134.13, 129.73, 128.89, 126.89, 126.17, 121.49, 115.43, 61.46, 40.65, 33.94, 28.33, 
15.91, 14.55. MS (ESI): calcd. 390.104; found 390.20 [M+H]+. 
 
 
Ethyl 5-methyl-4-(methylamino)-2-(3-(trifluoromethyl)phenethyl)thieno[2,3-d]pyrimidine-6-
carboxylate 10(w,a)  
Isolated 128 mg (50% yield) as a pale yellow semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.52 (s, 
1H), 7.37 (m, 3H), 5.66 (br. m, NH), 4.32 (q, J = 7.1 Hz, 2H), 3.25 – 3.11 (m, 4H), 3.09 (d, J = 
4.8 Hz, 3H), 2.87 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 167.77, 167.36, 
163.25, 159.60, 142.95, 138.20, 132.09, 130.62 (d, J = 31.9 Hz), 128.88, 125.52 (d, J = 3.8 Hz), 
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122.87 (d, J = 3.8 Hz), 121.55, 115.43, 61.46, 40.61, 34.04, 28.26, 15.88, 14.51. MS (ESI): calcd. 
424.131; found 424.27 [M+H]+. 
 
Ethyl 2-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(z,a)  
Isolated 62 mg (41% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.08 (m, NH), 
6.81 (s, 1H), 6.76 (dd, J = 7.9, 2.0 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 5.92 (s, 2H), 4.27 (q, J = 7.1 
Hz, 2H), 3.33 (s, 3H), 3.02 – 2.93 (m, 7H), 2.86 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, DMSO) δ 168.23, 167.95, 163.50, 159.82, 148.24, 146.36, 141.08, 136.55, 122.20, 120.06, 
115.93, 109.95, 109.16, 101.71, 62.16, 41.56, 34.09, 29.27, 16.73, 15.33. MS (ESI): calcd. 
400.13; found 400.40 [M+H]+. 
 
Dimethyl thiophene-2,5-dicarboxylate (13) 
An ice-cooled pressure vessel was charged with thiophene-2,5-carboxylic acid (2.5 g, 14.5 mmol) 
and 50 mL anhydrous MeOH; thionyl chloride (4.2 mL, 58 mmol) was added dropwise via 
syringe and once gas evolution had ceased the vessel was tightly sealed with a Teflon screw cap. 
The reaction was stirred 1h at RT and 3h at 60°C. The reaction mixture was cooled to RT and 
stirred open to air for 1h. The crude reaction mixture was diluted with 100 mL DCM, stirred for 
1h and decanted. The residue was collected by filtration and washed with DCM to obtain the 
desired product as a whit powder, 2.9 g (99% yield). 1H NMR (300 MHz, DMSO) δ 7.81 (s, 2H), 
3.85 (s, 6H). 13C NMR (126 MHz, DMSO) δ 162.40, 139.25, 134.94, 53.99. 
 
Dimethyl 3-aminothiophene-2,5-dicarboxylate (14) 
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An ice-cooled round-bottom flask was charged with 12 (1.0 g, 5.0 mmol), followed by 5 mL 
sulfuric acid. Nitric acid (0.50 mL, 6.2 mmol) was added slowly dropwise via syringe and the 
reaction was stirred at RT for 1 h. The crude reaction mixture was carefully poured on ice-water 
and stirred for 1h. The suspension was filtered, washed with water and dried on high vacuum to 
furnish dimethyl 3-nitrothiophene-2,5-dicarboxylate as a white solid, 1.1 g (93% yield). 1H NMR 
(500 MHz, DMSO) δ 8.22 (s, 1H), 3.88 (s, 6H). 13C NMR (126 MHz, DMSO) δ 161.14, 159.81, 
148.22, 136.58, 133.46, 129.26, 55.05, 54.53. 
A round-bottom flask was charged with dimethyl 3-nitrothiophene-2,5-dicarboxylate (1.0 g, 4.1 
mmol), suspended in MeOH/THF 2:1 and purged with nitrogen. Pearlman’s catalyst was added 
(286 mg, 2.0 mmol, 20% Pd(OH)2/C, CAS 12135-22-7), and the reaction mixture was purged 
with H2 gas and equipped with an H2-filled balloon. The reaction was stirred at RT until complete 
consumption of starting material, as determined by TLC. The reaction mixture was purged with 
nitrogen and filtered through a plug of Celite, rinsing with EtOAc. The filtrate was concentrated 
in vacuo and the obtained material was used as such without further purification. Isolated 900 mg 
(100% yield) as a yellow powder. 1H NMR (500 MHz, DMSO) δ 7.22 (s, 1H), 6.62 (s, NH2), 3.80 
(s, 3H), 3.74 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.82, 162.69, 155.01, 136.68, 126.34, 
103.33, 53.84, 52.61. 
 
Thienopyrimidinone formation, amine coupling and ester saponification performed as described 
in the general procedures. 
Methyl 4-(methylamino)-2-phenethylthieno[3,2-d]pyrimidine-6-carboxylate 16(d,a) 
Isolated 106 mg (51% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.98 (m, NH), 7.84 
(s, 1H), 7.22 (m, 4H), 7.12 (m, 1H), 3.87 (s, 3H), 3.13 – 3.04 (m, 4H), 2.98 (d, J = 4.5 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ 167.61, 163.19, 159.25, 158.42, 142.92, 137.95, 130.96, 129.43, 
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129.35, 126.84, 117.58, 54.06, 34.81, 26.99, 26.93. MS (ESI): calcd. 328.11; found 328.27 
[M+H]+. 
 
Methyl 2-(3-methoxyphenethyl)-4-(methylamino)thieno[3,2-d]pyrimidine-6-carboxylate 16(h,a)  
Isolated 100 mg (64% yield) as a pale yellow oil. MS (ESI): calcd. 358.123; found 358.27 
[M+H]+ 
 
General procedure for the saponification of esters: 
To solution of ester (1 equivalent) in 2:1 THF/MeOH was added 1 M NaOH (3 equivalents) and 
water to bring the final solvent ratio to 2:1:1 THF/MeOH/H2O. In cases where the starting 
material was not fully dissolved, the solution was heated to 50 °C as necessary. The reaction was 
stirred at RT until complete consumption of starting material as determined by TLC. The reaction 
mixture was acidified to pH~3 with 1 M HCl and concentrated in vacuo. The resultant slurry was 
diluted with 5 mL water, filtered and washed successively with deionized water, and purification 
grade pentane. The obtained residue was dried on high vacuum to furnish the desired free 
carboxylic acids. 
 
5-Methyl-4-(methylamino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid (17) 
Isolated 32 mg (87% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.23 (m, 
4H), 7.16 (m, 1H), 7.07 (br. d, J = 4.4 Hz, NH), 3.10 – 3.06 (m, 2H), 3.02 – 2.98 (m, 5H), 2.87 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 166.82, 166.58, 164.06, 158.71, 141.62, 138.94, 128.33, 
128.26, 125.79, 120.64, 115.00, 40.18, 33.32, 28.11, 15.44. HRMS (ESI): calcd. 328.11197 for 
C17H18N3O2S; found 328.1112 [M+H]+. 
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4-((2-Aminoethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid (18)  
Isolated 15 mg (35% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.28 – 7.14 (m, 
4H), 7.04 (br. s, NH), 3.51 (m, 2H), 3.28 (m, 2H), 3.12 – 3.03 (m, 2H), 3.06 – 2.93 (m, 5H), 2.58 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 166.91, 166.32, 163.82, 158.03, 142.57, 139.42, 128.65, 
128.97, 126.02, 120.41, 114.63, 47.69, 41.31, 33.89, 25.16, 16.46. 
HRMS (ESI): calcd. 357.13852 for C18H21N4O2S; found 357.1389 [M+H]+. 
 
4-(Benzylamino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid (19) 
Isolated 40 mg (86% yield) as a white crystalline material. 1H NMR (500 MHz, DMSO) δ 7.96 
(br. s, NH), 7.41 (d, J = 7.1 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.25 – 7.21 (m, 1H), 7.19 (d, J = 7.5 
Hz, 2H), 7.15 – 7.08 (m, 3H), 4.79 (d, J = 5.8 Hz, 2H), 2.96 (m, 4H), 2.95 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 164.72, 163.63, 157.97, 140.85, 139.07, 138.84, 128.29, 128.29, 128.25, 127.47, 
126.84, 125.94, 122.31, 115.31, 44.39, 38.54, 32.66, 15.43. HRMS (ESI): calcd. 404.14327 for 
C23H22N3O2S; found 404.1432 [M+H]+. 
 
5-Methyl-2-phenethyl-4-(phenethylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid (20) 
Isolated 28 mg (60% yield) as a white crystalline material. 1H NMR (500 MHz, DMSO) δ 7.34 – 
7.19 (m, 9H), 7.17 – 7.13 (m, 1H), 7.11 (br. t, J = 5.7 Hz, NH), 3.74 (dd, J = 14.6, 6.0 Hz, 2H), 
3.11 (dd, J = 8.5, 6.3 Hz, 2H), 3.03 (dd, J = 8.5, 6.2 Hz, 2H), 2.95 – 2.89 (m, 2H), 2.81 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 166.79, 164.03, 158.14, 141.56, 139.58, 138.76, 128.73, 128.45, 
128.30, 128.28, 126.19, 125.83, 120.89, 114.87, 42.33, 40.13, 34.66, 33.37, 15.33. HRMS (ESI): 
calcd. 418.15892 for C24H24N3O2S; found 418.1557 [M+H]+. 
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4-((4-Methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(21)  
Isolated 36 mg (55% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.52 (m, NH), 
7.27 – 7.22 (m, 4H), 7.15 (m, J = 7.5 Hz, 3H), 6.86 (d, J = 8.7 Hz, 2H), 3.72 (dd, J = 14.3, 6.4 
Hz, 2H), 3.70 (s, 3H), 3.13 – 3.09 (m, 2H), 3.06 (m, 2H), 2.87 – 2.82 (m, 2H), 2.82 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 164.45, 158.96, 158.84, 141.58, 139.77, 131.93, 130.86, 129.57, 
129.40, 127.30, 116.56, 115.02, 56.16, 44.42, 34.63, 33.54, 16.15. HRMS (ESI): calcd. 448.16949 
for C25H26N3O3S; found 448.1695 [M+H]+. 
 
4-((3-Methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(22)  
Isolated 45 mg (68% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.31 (m, NH), 
7.25 – 7.19 (m, 5H), 7.16 – 7.12 (m, 1H), 6.81 (m, 2H), 6.77 (m, 1H), 3.75 (dd, J = 14.0, 6.4 Hz, 
2H), 3.69 (s, 3H), 3.13 – 3.08 (m, 2H), 3.06 – 3.01 (m, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.81 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 164.79, 160.49, 159.06, 142.11, 141.96, 139.82, 130.61, 129.49, 
129.39, 127.13, 122.13, 116.29, 115.49, 112.80, 56.01, 43.78, 35.68, 34.00, 16.28. HRMS (ESI): 
calcd. 448.16949 for C25H26N3O3S; found 448.1684 [M+H]+. 
 
4-((2-Methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(23)  
Isolated 28 mg (60% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.26 – 7.13 
(m, 7H, NH), 6.95 (d, J = 7.7 Hz, 1H), 6.86 (t, J = 7.3 Hz, 1H), 3.73 (m, 5H), 3.10 (m, 2H), 3.01 
(m, 2H), 2.92 (t, J = 7.1 Hz, 2H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.67, 159.08, 
158.45, 141.93, 139.86, 131.43, 129.53, 129.39, 128.95, 128.07, 127.19, 121.48, 116.36, 111.85, 
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56.38, 42.62, 33.72, 30.29, 16.20. HRMS (ESI): calcd. 448.16949 for C25H26N3O3S; found 
448.1681 [M+H]+. 
 
4-((4-Fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(24)  
Isolated 23 mg (35% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.28 – 7.20 
(m, 5H, NH), 7.12 (m, 4H), 3.71 (dd, J = 13.8, 6.2 Hz, 2H), 3.11 – 3.06 (m, 2H), 3.03 – 2.98 (m, 
2H), 2.89 (t, J = 7.4 Hz, 2H), 2.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 165.01, 162.00 (d, J = 
241.5 Hz), 159.18, 142.45, 139.87, 136.73 (d, J = 3.0 Hz), 131.63 (d, J = 7.9 Hz), 129.44, 129.40, 
127.01, 116.24 (d, J = 21.0 Hz), 116.08, 43.52, 34.82, 34.30, 16.41. HRMS (ESI): calcd. 
436.14950 for C24H23FN3O2S; found 436.1473 [M+H]+. 
 
4-((3-Fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(25)  
Isolated 30 mg (46% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.41 (m, NH), 
7.32 (dd, J = 14.4, 7.8 Hz, 1H), 7.26 – 7.21 (m, 4H), 7.16 – 7.12 (m, 1H), 7.07 (m, 2H), 7.02 (td, 
J = 8.8, 2.5 Hz, 1H), 3.77 (dd, J = 13.9, 6.3 Hz, 2H), 3.12 – 3.07 (m, 2H), 3.06 – 3.02 (m, 2H), 
2.93 (t, J = 7.3 Hz, 2H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.44, 163.37 (d, J = 243.2 
Hz), 158.87, 143.12 (d, J = 7.4 Hz), 141.59, 139.72, 131.41 (d, J = 8.3 Hz), 129.54, 129.39, 
127.28, 126.12, 126.10, 124.37, 116.64 (d, J = 14.6 Hz), 116.54, 114.25 (d, J = 20.8 Hz), 43.76, 
38.43, 35.12, 33.58, 16.14. HRMS (ESI): calcd. 436.14950 for C24H23FN3O2S; found 436.1479 
[M+H]+. 
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4-((2-Fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(26)  
Isolated 21 mg (32% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.32 – 7.19 
(m, 6H, NH), 7.12 (m, 3H), 3.76 (dd, J = 13.8, 6.7 Hz, 2H), 3.08 (m, 2H), 3.02 – 2.93 (m, 4H), 
2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.90, 161.97 (d, J = 243.3 Hz), 159.18, 142.33, 
139.88, 132.52 (d, J = 5.0 Hz), 129.59, 129.53, 129.47, 129.39, 127.10 (d, J = 16.1 Hz), 127.06, 
125.55 (d, J = 3.3 Hz), 116.32 (d, J = 21.8 Hz), 116.16, 42.24, 34.08, 29.25, 16.34. HRMS (ESI): 
calcd. 436.14950 for C24H23FN3O2S; found 436.1476 [M+H]+. 
 
5-Methyl-4-((4-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(27)  
Isolated 48 mg (73% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.33 (m, NH), 
7.26 – 7.21 (m, 4H), 7.16 – 7.09 (m, 5H), 3.72 (dd, J = 14.4, 6.2 Hz, 2H), 3.12 – 3.08 (m, 2H), 
3.06 – 3.02 (m, 2H), 2.88 – 2.83 (m, 2H), 2.81 (s, 3H), 2.25 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 164.64, 158.94, 141.90, 139.78, 137.16, 136.36, 130.15, 129.73, 129.52, 129.38, 127.19, 
116.37, 44.09, 35.17, 33.81, 21.80, 16.25. HRMS (ESI): calcd. 432.17457 for C25H26N3O2S; 
found 432.1719 [M+H]+. 
 
5-Methyl-4-((3-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(28)  
Isolated 42 mg (64% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.45 (m, NH), 
7.25 – 7.22 (m, 4H), 7.20 – 7.13 (m, 2H), 7.07 (s, 1H), 7.02 (m, 2H), 3.74 (dd, J = 14.6, 6.1 Hz, 
2H), 3.12 (m, 2H), 3.06 (m, 2H), 2.89 – 2.84 (m, 2H), 2.81 (s, 3H), 2.25 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 164.43, 158.82, 141.57, 140.02, 139.73, 138.61, 130.58, 129.56, 129.50, 129.38, 
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128.09, 127.30, 126.94, 116.59, 44.26, 38.35, 35.44, 33.55, 22.15, 16.12. HRMS (ESI): calcd. 
432.17457 for C25H26N3O2S; found 432.1728 [M+H]+. 
 
5-Methyl-4-((2-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(29)  
Isolated 55 mg (84% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.42 (m, NH), 
7.27 – 7.21 (m, 4H), 7.17 – 7.12 (m, 3H), 7.12 – 7.08 (m, 2H), 3.68 (dd, J = 15.5, 5.8 Hz, 2H), 
3.11 – 3.06 (m, 2H), 3.04 – 2.99 (m, 2H), 2.93 – 2.88 (m, 2H), 2.85 (s, 3H), 2.40 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 164.75, 159.07, 142.05, 139.79, 138.43, 137.20, 131.24, 130.55, 
129.52, 129.33, 127.51, 127.16, 127.08, 116.25, 42.76, 34.25, 33.47, 20.10, 16.39. HRMS (ESI): 
calcd. 432.17457 for C25H26N3O2S; found 432.1746 [M+H]+. 
 
5-Methyl-2-phenethyl-4-((2-(pyridin-4-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(30)  
Isolated 42 mg (64% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.47 (d, J = 5.8 Hz, 
2H), 7.28 (d, J = 5.7 Hz, 2H), 7.25 – 7.20 (m, 4H), 7.13 (m, NH, 1H), 3.77 (dd, J = 13.4, 6.6 Hz, 
2H), 3.09 – 3.05 (m, 2H), 3.00 (m, 2H), 2.93 (t, J = 7.2 Hz, 2H), 2.80 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 168.00, 167.89, 165.14, 159.23, 150.30, 142.65, 139.84, 129.42, 129.41, 126.95, 
125.59, 122.11, 116.00, 42.20, 41.19, 35.03, 34.47, 16.48. HRMS (ESI): calcd. 419.15417 for 
C23H23N4O2S; found 419.1537 [M+H]+. 
 
5-Methyl-2-phenethyl-4-((2-(pyridin-3-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(31)  
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Isolated 41 mg (87% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.45 (s, 1H), 8.40 
(d, J = 4.7 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.30 (dd, J = 7.7, 4.8 Hz, 1H), 7.25 – 7.20 (m, 4H), 
7.13 (m, 1H, NH), 3.75 (dd, J = 13.3, 6.7 Hz, 2H), 3.07 (dd, J = 8.4, 6.1 Hz, 2H), 2.99 (dd, J = 
8.5, 6.3 Hz, 2H), 2.92 (t, J = 7.2 Hz, 2H), 2.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 168.00, 
167.89, 165.15, 159.25, 151.01, 148.56, 142.67, 139.82, 137.49, 136.22, 129.41, 126.94, 124.63, 
122.11, 115.97, 42.86, 41.23, 34.49, 32.89, 16.47. HRMS (ESI): calcd. 419.15417 for 
C23H23N4O2S; found 419.1537 [M+H]+. 
 
5-Methyl-2-phenethyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(32)  
Isolated 57 mg (87% yield) as an off white solid. 1H NMR (500 MHz, DMSO) δ 8.56 (d, J = 4.9 
Hz, 1H), 7.83 (m, NH), 7.41 – 7.32 (m, 3H), 7.24 – 7.21 (m, 4H), 7.15 – 7.11 (m, 1H), 3.89 (dd, J 
= 12.4, 6.6 Hz, 2H), 3.12 (t, J = 6.7 Hz, 2H), 3.05 (m, 2H), 2.96 (m, 2H), 2.84 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 167.80, 165.14, 159.92, 159.17, 148.62, 142.70, 139.82, 139.46, 129.42, 
129.38, 126.90, 125.32, 123.35, 122.12, 115.99, 41.44, 41.17, 36.77, 34.40, 16.42. MS (ESI): 
calcd. 419.15417 for C23H23N4O2S; found 419.1545 [M+H]+ 
 
2-(4-Acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(33)  
Isolated 27 mg (72% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 9.85 (s, 
NHAc), 7.46 (m, NH), 7.44 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.3 Hz, 2H), 3.03 (m, 7H), 2.87 (s, 
3H), 1.99 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.25, 164.47, 159.15, 139.96, 138.66, 
136.03, 129.62, 124.20, 120.16, 116.72, 38.55, 33.04, 30.12, 25.10, 16.22. HRMS (ESI): calcd. 
385.13344 for C19H21N4O3S; found 385.1336 [M+H]+. 
Page 56 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 57 
 
2-(3-Acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(34)  
Isolated 23 mg (62% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.84 (s, NHAc), 
7.47 (s, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.15 (t, J = 7.8 Hz, 1H), 7.08 (m, NH), 6.90 (d, J = 7.9 Hz, 
1H), 3.05 – 2.94 (m, 7H), 2.86 (s, 3H), 2.00 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.33, 
167.60, 165.14, 159.80, 143.12, 140.46, 140.07, 129.69, 124.16, 121.93, 120.00, 117.75, 116.19, 
34.57, 29.33, 25.18, 16.55. HRMS (ESI): calcd. 385.13344 for C19H21N4O3S; found 385.1333 
[M+H]+. 
 
2-(2-Acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(35)  
Isolated 13 mg (46% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 9.40 (s, 
NHAc), 7.32 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 7.14 (m, NH), 7.08 (m, 2H), 3.08 – 
3.02 (m, 2H), 2.98 (d, J = 4.4 Hz, 3H), 2.96 – 2.91 (m, 2H), 2.86 (s, 3H), 2.04 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 169.54, 168.12, 165.17, 159.83, 140.10, 137.22, 136.98, 130.26, 127.28, 
126.57, 121.82, 116.18, 30.04, 29.25, 24.42, 16.58. HRMS (ESI): calcd. 385.13344 for 
C19H21N4O3S; found 385.1331 [M+H]+. 
 
4-((2,3-Dihydro-1H-inden-2-yl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylic acid (36)  
Isolated 47 mg (72% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.25 – 7.19 
(m, 5H, NH), 7.17 – 7.12 (m, 3H), 6.91 (d, J = 7.0 Hz, 1H), 5.07 – 4.98 (m, 1H), 3.36 – 3.28 (m, 
2H), 3.09 – 3.04 (m, 3H), 3.01 (m, 3H), 2.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 168.05, 
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167.84, 165.15, 159.46, 142.65, 142.33, 140.06, 129.41, 129.37, 127.58, 126.91, 125.53, 122.21, 
116.24, 53.03, 41.21, 39.86, 34.49, 16.39. HRMS (ESI): calcd. 430.15892 for C25H24N3O2S; 
found 430.1562 [M+H]+. 
 
4-((3,5-Dimethoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (37)  
Isolated 31 mg (82% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.24 – 7.22 
(m, 4H), 7.16 – 7.09 (m, 1H, NH), 6.41 (d, J = 2.2 Hz, 2H), 6.33 (t, J = 2.2 Hz, 1H), 3.73 (dd, J = 
14.5, 6.4 Hz, 2H), 3.67 (s, 6H), 3.10 (m, 2H), 3.01 (m, 2H), 2.87 – 2.82 (m, 2H), 2.81 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 165.08, 161.61, 159.21, 142.94, 142.57, 139.84, 129.42, 129.38, 
126.99, 116.05, 107.83, 99.15, 56.13, 43.42, 36.02, 34.40, 16.41. MS (ESI): calcd. 478.18005 for 
C26H28N3O4S; found 478.1782 [M+H]+. 
 
4-((2-(Benzo[d][1,3]dioxol-5-yl)ethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylic acid (38)  
Isolated 22 mg (47% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.18 (m, 5H, 
NH), 7.16 – 7.12 (m, 1H), 6.82 (m, 2H), 6.68 (dd, J = 7.9, 1.6 Hz, 1H), 5.95 (s, 2H), 3.70 (dd, J = 
14.0, 6.0 Hz, 1H), 3.13 – 3.06 (m, 2H), 3.02 (m, 2H), 2.85 – 2.78 (m, 5H). 13C NMR (126 MHz, 
DMSO) δ 164.83, 159.07, 148.43, 146.76, 142.18, 139.85, 134.16, 129.49, 129.40, 127.12, 
122.76, 116.24, 110.19, 109.33, 101.86, 43.92, 35.33, 34.07, 16.31. HRMS (ESI): calcd. 
462.14875 for C25H24N3O4S; found 462.1486 [M+H]+. 
 
5-Methyl-4-(methylamino)-2-(3-phenylpropyl)thieno[2,3-d]pyrimidine-6-carboxylic acid (39)  
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Isolated 36 mg (78% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.25 (m, 2H), 7.19 
(m, 2H), 7.14 (m, 1H, NH), 2.97 (d, J = 4.4 Hz, 3H), 2.84 (s, 3H), 2.69 (t, J = 7.5 Hz, 2H), 2.62 
(t, J = 7.6 Hz, 2H), 2.05 – 1.97 (m, 2H). 13C NMR (126 MHz, DMSO) δ 168.13, 165.10, 159.76, 
143.09, 140.03, 129.53, 129.38, 126.84, 121.96, 116.11, 38.83, 35.90, 30.49, 29.34, 16.50. MS 
(ESI): calcd 342.12762 for C18H20N3O2S; found 342.1256 [M+H]+. 
 
5-Methyl-4-(methylamino)-2-(4-phenylbutyl)thieno[2,3-d]pyrimidine-6-carboxylic acid (40) 
 Isolated 60 mg (86% yield) as white powder. 1H NMR (500 MHz, DMSO) δ 7.23 (t, J = 7.5 Hz, 
2H), 7.13 (m, 3H), 7.03 (br. m, NH), 2.94 (d, J = 4.4 Hz, 3H), 2.84 (s, 3H), 2.69 (t, J = 7.5 Hz, 
2H), 2.58 (t, J = 7.6 Hz, 2H), 1.76 – 1.68 (m, 2H), 1.63 – 1.55 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 168.72, 167.39, 165.17, 159.83, 143.33, 140.06, 129.42, 129.34, 126.74, 121.71, 
116.03, 39.49, 36.12, 31.86, 29.21, 28.41, 16.53. HRMS (ESI): calcd 356.14327 for 
C19H22N3O2S; found 356.1413 [M+H]+. 
 
2-(3-Methoxyphenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid (41)  
Isolated 66 mg (71% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.12 (t, J = 8.0 Hz, 
1H), 7.01 (m, NH), 6.77 (m, 2H), 6.68 (dd, J = 9.0, 1.6 Hz, 1H), 3.05 – 2.93 (m, 7H), 2.82 (s, 
3H). OCH3 signal obscured by water peak. 13C NMR (126 MHz, DMSO) δ 167.90, 167.48, 
165.15, 160.29, 159.80, 144.29, 140.03, 130.39, 121.82, 121.70, 116.09, 115.03, 112.39, 55.95, 
41.03, 34.37, 29.19, 16.48. MS (ESI): calc. 358.12254 for C18H20N3O3S; found 358.1208 [M+H]+. 
 
2-(3-Fluorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid (42)  
Isolated 77 mg (83% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.24 (m, 1H), 7.02 
(m, 2H, NH), 6.93 (m, 1H), 3.06 (t, J = 7.5 Hz, 2H), 3.00 – 2.95 (m, 2H), 2.94 (d, J = 4.5 Hz, 
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3H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.64, 167.50, 165.14, 163.28 (d, J = 242.8 
Hz), 159.77, 145.69 (d, J = 7.3 Hz), 140.01, 131.16 (d, J = 8.4 Hz), 125.58 (d, J = 2.6 Hz), 
121.85, 116.12 (d, J = 20.7 Hz), 116.09, 113.65 (d, J = 20.9 Hz), 40.65, 33.89, 29.17, 16.47. 
HRMS (ESI): calcd. 346.10255 for C17H17FN3O2S; found 346.1006 [M+H]+. 
 
5-Methyl-4-(methylamino)-2-(2-(pyridin-2-yl)ethyl)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(43)  
Isolated 46 mg (84% yield) as a white powder. 1H NMR (300 MHz, DMSO) δ 8.75 (d, J = 4.9 Hz, 
1H), 8.41 (td, J = 7.9, 1.5 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.82 (t, J = 6.3 Hz, 1H), 7.17 (br. m, 
NH), 3.47 (t, J = 7.1 Hz, 2H), 3.27 (t, J = 7.1 Hz, 2H), 2.80 (m, 6H). 13C NMR (75 MHz, DMSO) 
δ 165.80, 165.33, 164.51, 159.13, 157.64, 146.10, 142.19, 139.47, 127.38, 125.11, 121.94, 
115.76, 36.57, 31.33, 28.73, 15.89. HRMS (ESI): calcd. 329.10722 for C16H17N4O2S; found 
329.1067 [M+H]+. 
 
2-(4-Acetamidophenethyl)-4-((2-aminoethyl)amino)-5-methylthieno[2,3-d]pyrimidine-6-
carboxylic acid (44)  
Isolated 17 mg (36% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.84 (s, NHAc), 
8.50 (br. s, NH2), 7.56 (br. s, NH), 7.44 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 3.82 (m, 
2H), 3.15 (m, 2H), 3.03 (s, 3H), 3.00 (d, J = 7.2 Hz, 2H), 2.94 (d, J = 7.8 Hz, 2H), 2.00 (s, 3H). 
HRMS (ESI): calcd. 414.15999 for C20H24N5O3S; found 414.1591 [M+H]+. 
 
2-(4-Acetamidophenethyl)-5-methyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylic acid (45)  
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Isolated 33 mg (64% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NH), 8.51 
(d, J = 4.9 Hz, 1H), 7.71 (tt, J = 7.7, 1.9 Hz, 1H), 7.42 (d, J = 6.8 Hz, 2H), 7.36 (br. t, J = 4.8 Hz, 
NH), 7.28 (d, J = 7.8 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.13 (d, J = 6.9 Hz, 2H), 3.87 (dd, J = 12.2, 
5.5 Hz, 2H), 3.08 (t, J = 6.5 Hz, 2H), 3.04 – 2.99 (m, 2H), 2.97 – 2.93 (m, 2H), 2.85 (s, 3H), 1.99 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 169.20, 167.80, 165.22, 160.73, 159.22, 150.13, 138.30, 
137.87, 137.25, 129.57, 124.49, 122.79, 120.13, 116.03, 41.56, 41.31, 37.42, 33.89, 25.07, 16.32. 
HRMS (ESI): calcd. 476.17564 for C25H26N5O3S; found 476.1761 [M+H]+ 
 
2-(3-Chlorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid (46)  
Isolated 62 mg (67% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.28 (s, 1H), 7.25 – 
7.21 (m, 1H), 7.18 – 7.14 (m, 2H), 7.03 (m, NH), 3.07 – 3.02 (m, 2H), 2.97 (m, 2H), 2.94 (d, J = 
4.5 Hz, 3H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.47, 167.21, 165.11, 159.74, 145.25, 
140.00, 133.93, 131.16, 129.37, 128.21, 126.90, 121.93, 116.10, 40.51, 33.75, 29.20, 16.46. 
HRMS (ESI): calcd. 362.07300 for C17H17ClN3O2S; found 362.0719 [M+H]+. 
 
5-Methyl-4-(methylamino)-2-(3-(trifluoromethyl)phenethyl)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (47)  
Isolated 80 mg (86% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.55 (s, 1H), 7.46 
(m, 3H), 7.04 (br. m, NH), 3.14 (t, J = 7.5 Hz, 2H), 3.02 (t, J = 7.5 Hz, 2H), 2.92 (d, J = 4.4 Hz, 
3H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.36, 167.13, 165.10, 159.73, 144.05, 
139.97, 133.66, 130.31, 130.16, 129.91, δ 126.06 (q, J = 3.8 Hz), 123.66 (q, J = 3.9 Hz), 121.96, 
116.09, 33.79, 29.14, 16.44. HRMS (ESI):  calcd. 396.09936 for C18H17F3N3O2S; found 396.0975 
[M+H]+. 
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2-(2-(Benzo[d][1,3]dioxol-5-yl)ethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylic acid (48)  
Isolated 25 mg (54% yield) as white solid. 1H NMR (500 MHz, DMSO) δ 7.13 (br. s, NH), 6.82 
(s, 1H), 6.77 (d, J = 7.9 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 5.93 (s, 2H), 3.02 – 2.93 (m, 7H), 2.86 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 167.45, 165.09, 159.73, 148.25, 146.39, 140.07, 136.42, 
122.21, 122.05, 116.18, 109.95, 109.18, 101.72, 41.21, 34.01, 29.36, 16.53. HRMS (ESI): calcd. 
372.10180 for C18H18N3O4S; found 372.1021 [M+H]+. 
 
4-(methylamino)-2-phenethylthieno[3,2-d]pyrimidine-6-carboxylic acid (49)  
Isolated 40 mg (84% yield) as an off-white powder. 1H NMR (500 MHz, DMSO) δ 7.99 (m, NH), 
7.81 (s, 1H), 7.27 – 7.23 (m, 4H), 7.16 (m, 1H), 3.12 – 3.07 (m, 2H), 3.05 – 3.01 (m, 2H), 2.99 (d, 
J = 4.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.38, 164.21, 158.49, 142.88, 130.23, 129.48, 
129.39, 126.90, 41.32, 34.82, 28.44. HRMS (ESI): calcd. 314.09632 for C16H16N3O2S; found 
314.0962 [M+H]+. 
 
2-(3-Methoxyphenethyl)-4-(methylamino)thieno[3,2-d]pyrimidine-6-carboxylic acid (50) 
Isolated 78 mg (81% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.11 (br. d, J = 4.3 
Hz, 1H), 7.76 (s, 1H), 7.13 (t, J = 7.8 Hz, 1H), 6.81 – 6.75 (m, 2H), 6.68 (dd, J = 8.3, 1.7 Hz, 
1H), 3.04 – 2.99 (m, 4H), 2.97 (d, J = 4.4 Hz, 3H). OCH3 signal obscured by water peak. 13C 
NMR (126 MHz, DMSO) δ 167.10, 164.14, 160.30, 144.29, 130.40, 129.32, 121.72, 121.68, 
115.03, 112.40, 55.95, 40.79, 34.69. HRMS (ESI): calcd. 344.10689 for C17H18N3O3S; found 
344.1072 [M+H]+. 
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Ethyl 4-(((R)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate – 51 (precursor)  
Isolated 101 mg (53% yield) as a colorless syrup. 1H NMR (500 MHz, DMSO) δ 7.38 (m, 2H), 
7.34 – 7.28 (m, ), 7.22 (m, 5H), 7.10 (t, J = 6.8 Hz, 1H), 6.96 (br. t, J = 5.5 Hz, NH), 4.54 (dd, J = 
7.5, 5.3 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.76 – 3.69 (m, 1H), 3.69 – 3.61 (m, 1H), 3.43 (m, 1H), 
3.18 (s, 3H), 2.96 (m, 2H), 2.76 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H). 13C 
NMR (75 MHz, DMSO) δ 167.65, 167.15, 162.87, 158.58, 147.31, 140.51, 140.03, 129.07, 
128.85, 128.46, 127.41, 127.19, 126.50, 120.06, 115.15, 81.57, 79.84, 61.61, 57.16, 47.51, 39.04, 
22.62, 15.94, 14.75. MS (ESI): calcd. 490.22; found 490.33 [M+H]+. 
 
4-(((R)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (51)  
Isolated 13 mg (28% yield) as white solid. 1H NMR (500 MHz, DMSO) δ 7.38 (m, 2H), 7.31 (m, 
3H), 7.22 (m, 4H), 7.12 – 7.08 (m, 1H), 6.85 (br. s, NH), 4.54 (m, 1H), 3.72 (m, 1H), 3.68 – 3.60 
(m, 1H), 3.18 (s, 3H), 3.02 – 2.86 (m, 3H), 2.75 (s, 3H), 1.20 (d, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, DMSO) δ 167.68, 167.10, 165.30, 159.07, 147.85, 141.06, 129.60, 129.40, 128.99, 127.97, 
127.75, 127.04, 115.94, 82.06, 57.70, 47.98, 47.61, 39.57, 23.21, 16.17. HRMS (ESI): calcd. 
462.18514 for C26H28N3O3S; found 462.1853 [M+H]+ 
 
Ethyl 4-(((S)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate 52 (precursor)  
Isolated 31 mg (16% yield) as a colorless syrup. 1H NMR (500 MHz, DMSO) δ 7.41 – 7.36 (m, 
2H), 7.31 (m, 3H), 7.25 – 7.20 (m, 4H), 7.10 (m, 1H), 6.99 (br. t, J = 5.4 Hz, NH), 4.51 (dd, J = 
7.8, 4.7 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.79 – 3.73 (m, 1H), 3.62 (m, 1H), 3.44 (m, 1H), 3.17 
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(s, 3H), 2.95 (m, 2H), 2.78 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.22 (d, J = 7.0 Hz, 3H). 13C NMR 
(75 MHz, DMSO) δ 167.62, 167.17, 162.90, 158.60, 147.27, 140.52, 140.12, 129.11, 128.88, 
128.51, 127.45, 127.20, 126.54, 120.05, 115.17, 81.63, 61.68, 57.21, 47.49, 36.87, 24.96, 22.71, 
16.00, 14.80. MS (ESI): calcd. 490.22; found 490.40 [M+H]+. 
 
4-(((S)-2-Methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (52)  
Isolated 15 mg (53% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.39 (m, 2H), 7.31 
(m, 3H), 7.21 (m, 4H), 7.10 (m, 1H), 6.97 (m, NH), 4.51 (dd, J = 7.7, 4.4 Hz, 1H), 3.76 (m, 1H), 
3.62 (m, 1H), 3.17 (s, 3H), 2.95 (m, 3H), 2.77 (s, 3H), 1.22 (d, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, DMSO) δ 167.30, 165.07, 159.10, 147.75, 141.02, 139.64, 129.62, 129.40, 129.02, 127.97, 
127.73, 127.07, 122.30, 115.88, 82.12, 57.72, 47.89, 47.70, 39.49, 23.24, 16.32. HRMS (ESI): 
calcd. 462.18514 for C26H28N3O3S; found 462.1857 [M+H]+. 
 
Ethyl 4-(((R)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate 53 (precursor)  
Isolated 65 mg (63% yield) as pale yellow syrup. 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.20 (m, 
9H), 7.16 – 7.09 (m, 1H), 6.11 (br. t, NH), 4.41 – 4.31 (m, 3H), 4.08 (ddd, J = 13.8, 7.2, 4.0 Hz, 
1H), 3.56 – 3.44 (m, 2H), 3.30 (s, 3H), 3.17 – 2.96 (m, 2H), 2.87 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H), 
1.29 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 163.33, 158.77, 147.18, 139.30, 138.36, 
128.97, 128.57, 128.47, 127.27, 126.87, 126.13, 115.37, 82.07, 61.45, 57.25, 47.11, 39.30, 24.96, 
22.09, 15.71, 14.56. MS (ESI): calcd. 490.22; found 490.33 [M+H]+. 
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4-(((R)-2-Methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (53)  
Isolated 43 mg (76% yield) as white solid. 1H NMR (500 MHz, DMSO) δ 7.39 (m, 2H), 7.31 (m, 
3H), 7.25 – 7.18 (m, 4H), 7.12 – 7.07 (m, 1H), 7.04 ( br. t, J = 5.4 Hz, NH), 4.50 (dd, J = 7.9, 4.7 
Hz, 1H), 3.80 – 3.73 (m, 1H), 3.66 – 3.61 (m, 1H), 3.17 (s, 3H), 2.96 (m, 4H), 2.77 (s, 3H), 1.22 
(d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.06, 165.01, 159.08, 147.65, 140.95, 
139.63, 129.63, 129.42, 129.04, 127.96, 127.73, 127.10, 122.47, 115.92, 82.10, 68.17, 57.72, 
47.73, 39.47, 23.22, 16.28. HRMS (ESI): calcd. 462.18514 for C26H28N3O3S; found 462.1847 
[M+H]+. 
 
Ethyl 4-(((S)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate 54 (precursor)  
Isolated 67 mg (65% yield) as a colorless syrup. 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.32 (m, 
5H), 7.30 – 7.19 (m, 4H), 7.13 (dt, J = 9.3, 4.2 Hz, 1H), 6.11 (br. t, NH), 4.39 (m, 3H), 4.06 (ddd, 
J = 13.7, 7.0, 4.1 Hz, 1H), 3.57 – 3.44 (m, 2H), 3.31 (s, 3H), 3.08 (m, 2H), 2.87 (s, 3H), 1.38 (t, J 
= 6.2 Hz, 3H), 1.27 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 163.33, 158.78, 147.22, 
139.29, 138.35, 128.97, 128.57, 128.47, 127.26, 126.88, 126.12, 115.37, 82.06, 61.45, 57.24, 
47.06, 39.28, 36.93, 22.18, 15.68, 14.55. MS (ESI): calcd. 490.22; found 490.33 [M+H]+. 
 
4-(((S)-2-Methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (54)  
Isolated 42 mg (74% yield) as a yellow solid. 1H NMR (500 MHz, DMSO) δ 7.41 – 7.36 (m, 2H), 
7.34 – 7.29 (m, 3H), 7.26 – 7.19 (m, 4H), 7.12 – 7.08 (m, 1H), 7.00 (br. t, J = 5.5 Hz, NH), 4.54 
(dd, J = 7.6, 5.1 Hz, 1H), 3.76 – 3.70 (m, 1H), 3.69 – 3.62 (m, 1H), 3.18 (s, 3H), 2.96 (m, 3H), 
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2.75 (s, 3H), 1.20 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.12, 165.02, 159.09, 
147.68, 140.96, 139.62, 129.62, 129.43, 129.04, 127.96, 127.75, 127.10, 122.45, 115.91, 82.02, 
68.17, 57.70, 47.71, 39.55, 23.20, 16.25. HRMS (ESI): calcd. 462.18514 for C26H28N3O3S; found 
462.1847 [M+H]+. 
 
Ethyl (S)-2-(4-acetamidophenethyl)-4-((2-methoxy-2-phenylethyl)amino)-5-methylthieno[2,3-
d]pyrimidine-6-carboxylate 55 (precursor)  
Isolated 40 mg (82% yield, over two steps) as a white powder. 1H NMR (300 MHz, CDCl3) δ 7.55 
(s, 1H), 7.41 (m, 7H), 7.15 (d, J = 8.4 Hz, 2H), 6.16 (br. m, NH), 4.43 (dd, J = 8.6, 3.8 Hz, 1H), 
4.34 (q, J = 7.1 Hz, 2H), 4.14 (ddd, J = 14.0, 7.0, 4.3 Hz, 1H), 3.54 (ddd, J = 13.7, 8.7, 3.8 Hz, 
1H), 3.31 (s, 3H), 3.07 (m, 4H), 2.88 (s, 3H), 2.12 (s, 3H), 1.38 (t, J = 7.1 Hz, 4H). 13C NMR (75 
MHz, CDCl3) δ 163.32, 158.91, 150.73, 137.95, 129.11, 128.98, 126.87, 120.18, 115.46, 84.48, 
61.49, 57.24, 47.08, 41.08, 33.87, 24.72, 15.72, 14.55. MS (ESI): calcd. 533.22; found 
533.27[M+H]+. 
 
 (S)-2-(4-Acetamidophenethyl)-4-((2-methoxy-2-phenylethyl)amino)-5-methylthieno[2,3-
d]pyrimidine-6-carboxylic acid (55)  
Isolated 24 mg (63% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.81 (s, NHAc), 
7.43 (d, J = 8.5 Hz, 2H), 7.39 – 7.28 (m, 5H), 7.12 (d, J = 8.5 Hz, 2H), 6.98 (br. t, J = 5.2 Hz, 
NH), 4.54 (dd, J = 7.7, 5.0 Hz, 1H), 3.80 (m, 1H), 3.67 (m, 1H), 3.18 (s, 3H), 2.98 (m, 4H), 2.79 
(s, 3H), 1.98 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.15, 167.82, 165.09, 159.21, 141.02, 
139.66, 138.37, 137.11, 129.61, 129.55, 129.00, 127.75, 122.32, 120.10, 115.96, 82.14, 57.69, 
47.66, 41.28, 33.91, 25.08, 16.33. HRMS (ESI): calcd. 505.19095 for C27H29N4O4S; found 
505.1916 [M+H]+. 
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Protein expression and purification:  
The heterologous expression of PglD was accomplished using the E. coli BL-21(DE3) strain 
(Stratagene). Cells were transformed with pETNO-construct plasmids and grown to an A600 of 
0.6 absorbance units at 37 °C in Lysogeny broth; the cultures were cooled to 16 °C and then 
induced by the addition of 0.5 mM isopropyl-D-thiogalactopyranoside (IPTG). The pETNO 
plasmid is based on the pET30a plasmid modified to include a His8TEV (purification tag/protease 
cleavage site) in place of the existing His6-thrombin site. Twenty hours after induction the cells 
were harvested by centrifugation and resuspended in ice-cold buffer composed of 50 mM HEPES 
pH 7.1, 10 mM imidazole, 150 mM NaCl, at1⁄20 the original culture volume. Maintaining a 
working temperature of 4 °C, the cells were lysed by sonication, and the lysate was cleared by 
centrifugation in a Type 45 Ti rotor (Beckman/Coulter) at 35,000 rpm. The extract was bound to 
Ni-NTA (Qiagen) in batch mode using 1 mL of resin per liter of culture for 1h with gentle 
tumbling. The protein-bound resin was washed with 25 column volumes of lysis buffer containing 
50 mM imidazole, and the protein was eluted in lysis buffer containing 250 mM imidazole. The 
hexahistidine tag was removed by TEV cleavage, and after the digest reached completion, the 
reaction was dialyzed twice against 4 L 20 mM HEPES pH 7.1, 150 mM NaCl with a 10,000 
MWCO Snakeskin (Thermo Scientific). Further purification was performed by size exclusion 
chromatography using a Superdex 200 XK16–60 column (GE Healthcare) in a running buffer of 
20 mM HEPES pH 7.1, 100 mM NaCl. 
 
High-throughput screening – Broad Institute MLPCN 
To a Nunc 384-well black-clear bottom plate (Thermo Scientific) was added 200 nL of compound 
in neat DMSO (final assay concentration = 10 µM) and 20 µL of enzyme solution (final assay 
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concentrations: 6 nM PglD, 50 mM HEPES pH 7.4, 0.001% Triton, 0.05% BSA, 100 µM 
AcCoA). Solution dispensing was accomplished utilizing a Multidrop Combi (Thermo Scientific). 
This mixture was allowed to incubate at room temperature for a duration of 45 minutes. The 
reaction was started by the addition of 10 µL reaction solution (final assay concentrations: 50 mM 
HEPES pH7.4, 100 µM UDP-4-aminosugar). The reaction was quenched after 30 minutes with 
the addition of 30 µL stop solution (final assay concentrations: 2 mM DTNB, 1 mM EDTA, 20% 
1-propanol). The plates were allowed to develop for 5 minutes before reading at a λ = 405 nm. 
 
Enzymatic inhibition assay 
Kinetic characterization of PglD inhibition was carried out by monitoring CoASH release 
resulting from the acetyltransferase reaction with Ellman’s reagent (DTNB) in a continuous 
fashion. To a flat, clear bottom 96-well plate (Falcon) was added sequentially the inhibitor as a 
DMSO stock solution, followed by PglD in 50 mM HEPES pH 7.8, 1 mM MgCl2, 0.05 mg/mL 
BSA, 0.001% Triton X-100. Inhibitors and enzyme were pre-incubated 30 min at RT, followed by 
addition of substrate and Ellman’s reagent cocktail to final concentrations of 3 nM PglD, 500 µM 
4-amino-sugar, 300 µM AcCoA, 2 mM DTNB and 3% DMSO in 150 µL volume. Initial rates 
were measured in the linear portion of the reaction curve over a 5 min time period at RT, 
measuring absorbance at 412 nm on a Synergy H1 hybrid plate reader from Biotek. 
 
Dynamic Light Scattering 
Samples were prepared in buffer 50 mM HEPES 7.5, 100 mM NaCl and a final concentration of 
3% DMSO; the concentration of C jejuni PglD was 25 µM with or without 250 µM inhibitor 57. 
DLS data was acquired on a Wyatt DynaPro Nanostar Light Scatterer by measuring scattering at a 90° 
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angle with a 685 nm laser and analyzed with a Rayleigh scattering model using the Dynamics 7.1.9 
software package. 
 
Differential Scanning Fluorimetry 
Samples were prepared to a final volume of 25 µL containing 10 µM PglD protein and 100 µM 
inhibitor in a buffer containing 50 mM HEPES 7.5, 150 mM NaCl, 0.001 % Triton X-100, 10x 
Sypro orange (diluted from a commercial stock solution of 5000X; Invitrogen) and a final 
concentration of 3% DMSO. All samples were prepared in duplicate. Fluorescence was measured 
using a Roche Lightcycler 480 RT-PCR instrument while increasing the temperature gradient 
from 30 to 95°C in increments of 4.4°C/60 s. The midpoint temperature of the unfolding protein 
transition (Tm) was calculated using the built-in functionality of the instrument software package. 
 
Crystallization of C. jejuni PglD in complex with inhibitor 17 
Initial crystallization screening was performed by sitting drop vapor diffusion using intelli-plate® 
from Hampton Research with 50 µL/well solution, which was dispensed as a 0.15 µL drop 
followed 0.15 µL of 10 mg/mL PglD solution in SEC buffer. Screens used were PEG suite 1, PEG 
suite 2, PACT and ProComp from Qiagen, and drops were set up using an Art Robbins Phoenix 
robot. Diffraction quality crystals were formed via hanging drop vapor diffusion by mixing 1.5 
µL of protein solution with 1.5 µL of reservoir solution (15% PEG-3350, 0.1M NaF and 10% 
glycerol) and incubation at 22 °C.  
Ligand soaking: Wells were carefully opened and 50 µL of DMSO was added directly to the well; 
0.75 µL of a solution containing 10 mM inhibitor 17 in reservoir solution (final concentration of 
10% DMSO) was added directly to the drops on the slide. The crystals were then incubated for 30 
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min to 3 days, and then looped and flash frozen in liquid nitrogen without the need of separate 
cryoprotection.  
 
Data Collection, Processing, and Structure Refinement 
Diffraction data was collected either at a home source (Rigaku Saturn 944 with MicroMax-007 
HF and VariMax HF generator) or at the Advanced Photon Source (APS) at Argonne National 
Laboratory (in Argonne, Illinois, USA) national synchrotron on the NECAT-24ID beamline. 
The diffraction data were indexed and scaled with either HKL2000. The initial structure model 
was built by applying molecular replacement methods with a ligand/solvent-omitted input model 
generated from the PDB model 3BSY. The initial models were further improved through iterative 
rounds of manual and automated refinement with COOT.56 The final structure has been deposited 
into the Protein Data Bank PDB ID 5T2Y. Data collection and refinement statistics are presented 
in in the supporting information Table S3  
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Supporting Information 
Supporting information accompanying this paper includes NMR spectra and LC-MS 
chromatograms of selected inhibitors, molecular formula strings table, enzyme inhibition studies, 
DLS studies, and X-ray crystallography data. 
 
PDB IDs: 5T2Y and 5TYH The atomic coordinates and experimental data will be released on the 
PDB upon article publication.  
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diNAcBac: 2,4-diacetamido-2,4,6-trideoxy-a-D-glucose 
PyBOP: (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
DSF: Differential scanning fluorimetry 
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PLP: Pyridoxal 5′-phosphate 
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STD: saturation transfer difference 
UndP: undecaprenyl phosphate  
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